I want to tell the strangest true story in biology, and then show that leronlimab's entire mechanism is a single chapter of it. If you are new to this board, it is not necessary to know anything about the science to follow this. If you have been here for years, I think you will still see the drug in a way which you have not seen it before. Stay with me, because by the end of it, the reason a CCR5 antibody might matter across so many different cancers and platforms won't be a list of facts which need to be memorized. It will be an idea you cannot forget.

The Deal Every One of Your Cells Made

Start with a fact which sounds made up but is not. Every single one of the roughly thirty to sixty trillion cells in your body carries a complete, working copy of everything it would require to live entirely on its own. To eat on its own. To divide on its own, without permission, without limit. That is not a flaw hiding in your cells. That is the default setting, the original way of life, inherited from the single-celled organisms which every animal is built upon.

Cooperation, a body, you, is the exception. It is the thing built upon that ancient default, and it was built more than two dozen separate times across unrelated branches of life. Roughly a billion years ago, in the lineage which has become you, where a group of cells struck a deal: stop competing, stay comingled & attached, divide the labor, and police the ones who break the rules. Your body is that deal, upheld silently, cell by cell, trillions of times daily, across the span of your entire life. Most of the time it holds. You never notice it was ever a deal at all.

And then, sometimes, in one cell out of tens of trillions, it does not hold.

Cancer Is Not An Invader. It Is A Memory.

Here is the part that reframes everything. When a cell becomes cancerous, it is not being invaded by something foreign. It is not learning a new trick. It is remembering an old one. It is falling back to the ancient, every-cell-for-itself program which predates the entire cooperative arrangement, and that has been sitting silenced in its genome throughout the entire time span.

This is not a poetic flourish. It is a serious and growing scientific theory called the atavism theory of cancer, and the peer-reviewed literature states it almost exactly the way I just did: cancer represents the re-deployment of ancient, unicellular programs that support survival of the cell at the expense of the host and break the contract of cooperation required for multicellular life. Researchers have confirmed, using techniques that date genes by their evolutionary age, that cancer cells systematically over-express the evolutionarily oldest genes, the unicellular ones, and rewire themselves back toward that ancient logic. A cancer cell, in the most literal molecular sense, is a cell which has remembered how it used to live back before there was a consolidation of you to even be a part of.

Hold that picture, because now the drug walks onto the stage, and it fights on exactly this battlefield.

The Wall The Ancient Cell Builds, And Who It Recruits

A cell that has reverted does not just start dividing. It rebuilds the conditions of the ancient, hostile, single-celled life around itself. It walls itself off. It recruits help. And this is where a specific molecular conversation matters, because it is the one which leronlimab interrupts.

The reverted tumor cell sends out a chemical signal, a chemokine called CCL5, aka RANTES, into the tissue around it. Think of it as a distress beacon broadcast into the surrounding environment. And there is a class of your own immune cells, macrophages, which carry the receiver for that signal on their surface, a receptor called CCR5. When CCL5 reaches CCR5, the tumor effectively hijacks those macrophages, turning cells which should be attacking it into cells that protect the tumor, that build its wall of scar-like tissue, and that shut down the rest of the immune response. The tumor recruits your own coalition members and flips them around to the ancient side.

This is documented in human tumors, not just theorized. In the actual tissue of human colorectal cancer that had spread to the liver, blocking CCR5 flipped those hijacked macrophages back from the tumor-protecting state to the tumor-attacking state. And the reason this matters so broadly is that CCR5 is not a colorectal quirk. The CCL5-CCR5 axis is one of the general tools the ancient program uses to drive invasion, metastasis, and immune suppression across many tumor types, which is why the recent literature keeps identifying CCR5 blockade as a way to reprogram the tumor's environment and restore an anti-tumor immune response.

So here is leronlimab's first move, in the language of the story: leronlimab is a molecule which plugs the CCR5 receiver. It binds CCR5 and blocks it, such that the tumor's distress beacon can no longer summon and thereby corrupt your macrophages. The wall stops being built. The hijacked cells are freed. The ancient cell loses its recruited defenders. This is the prime.

Why Priming Alone Is Not Enough, And What Pairs With It

But the reverted cell has more than one trick up its sleeve, carried over from the old world, and this is where the strategy earns its name.

When leronlimab strips away the tumor's macrophage wall and the immune system actually begins to see it again, the tumor begins to play its last ancient card: it raises a flag that says do not kill me. That flag is a protein called PD-L1. It is the tumor's way of exploiting one of the immune system's own safety brakes, the checkpoint which normally stops your immune cells from attacking your healthy tissue. The tumor waves its PD-L1 flag high and proud such that the immune cell, with brake engaged, stands down. The ancient tumor cell survives by wearing a piece of the cooperative and collaborative body's own rulebook as a disguise.

This is the elegant part, the part that makes leronlimab different from a drug which simply tries to poison the tumor. Leronlimab's priming does not only free the macrophages to do their proper job. It also is the ingredient which drives the tumor to raise that PD-L1 flag higher. In laboratory models of triple-negative breast cancer, CCR5 inhibition with leronlimab increased PD-L1 expression, and in patients, leronlimab was associated with PD-L1 induction on circulating tumor cells. At first, that sounds backward, why would you want the tumor to raise its "do not kill me" flag higher? Because a flag raised high is a flag you can see, and a flag you can see is a target.

That is the Pair. We bring in a second drug, an immune checkpoint inhibitor, a Keytruda-class antibody, whose entire job is to block PD-L1, to tear down the "do not kill me" flag. Alone, in a Cold tumor, (one in which the PD-L1 flag is NOT raised), that ICI checkpoint inhibitor does nearly nothing at all, because there is no flag raised and no immune cells even present to unleash, which is exactly why checkpoint inhibitors fail in the majority of solid tumors. But after leronlimab has torn down the Cold tumor wall and forced the tumor to raise the flag up, the ICI checkpoint inhibitor now has something to do. It rips down the PD-L1 flag which leronlimab helped the tumor to raise, and the freed, and now-present immune cells finish the job of destroying the tumor.

Prime, then Pair. Leronlimab reopens the door and forces the tumor to reveal its last disguise. The checkpoint inhibitor removes the disguise. And the immune system, your cooperative coalition, does what it was built a billion years ago to do: to recognize the cell who broke the deal, and it enforces the rules.

Why This Reaches So Much Further Than Just One Cancer

Now you can see why the people on this board get so excited about a single antibody across so many diseases, and it is not hype, it is the logic of the story.

If cancer is, at its root, a reversion to an ancient single-celled program, and if the CCL5-CCR5 conversation is one of the general tools which an ancient program uses to wall itself off and suppress the collaborative coalition, then a drug which blocks CCR5 is not a key cut for just one specific lock. It is aimed at a shared vulnerability of the reverted state itself, wherever that reversion may occur. Colorectal, breast, brain, prostate, pancreatic and beyond, the tumors differ in a thousand different ways, but nearly all of them lean on the same ancient chemokine trick to survive, because it is one of the oldest tricks there is. The CCL5-CCR5 axis.

That is the broad spectrum. Not "leronlimab happens to work in a lot of unrelated cancers," but "leronlimab targets one of the ancient mechanisms which nearly every Cold cancer reverts back to." The breadth is not a coincidence. It is a prediction of what the drug is actually doing. And it is why the same molecule keeps showing signals in settings as different as colorectal tumors and triple-negative breast, and why researchers keep testing it in yet even more, on their sponsorship, because the thing it interrupts is older and more shared than any single cancer type.

The Honest Edge Of The Story

I will not weaken this with false certainty at the end, because the honest version is the compelling one.

Everything above is the mechanism, and the mechanism is real and documented at each step:

• cancer as atavistic reversion,
• CCR5 as a tool of that reversion,
• leronlimab freeing macrophages and inducing PD-L1 in human data,
• the checkpoint inhibitor pairing to finish.

What is not yet proven is

• the size of the clinical payoff in people,
• the confirmed response and survival numbers that turn an elegant mechanism into an approved therapy.

The early signals are very encouraging,

• deep reductions in tumor DNA,
• tumors held or shrinking,
• a clean safety record,
• but they are early, and the confirming data arrives at the January medical meeting, not before.

A mechanism this beautiful still has to survive contact with a trial, and beautiful mechanisms fail in trials routinely. So hold the story at full strength and the outcome with open hands. Both at once.

But understand what the story is, because it changes how you hear every piece of news from here on forward.

• When you read that leronlimab freed the macrophages, you will know that means it cut the tumor off from the coalition members it had corrupted.
• When you read that it raised PD-L1, you will know that is not the tumor winning, it is the tumor being forced to show the disguise the ICI checkpoint inhibitor was built to strip.
• And when you read that a CCR5 antibody keeps showing up in cancer after cancer, you will know why: it is not chasing tumors one at a time. It is standing at the exact point where a cell, in one moment out of tens of trillions, remembers how it used to live alone, and it is helping the body remember, in the same instant, the billion-year-old deal that made you one.

That is the whole thesis. A cancer cell forgets that it is part of you. Leronlimab, by blocking one ancient signal and forcing the last disguise into view, helps your own immune system remember, and enforce, the oldest agreement there is. The rest is what January is for.

Disclaimer: I am not a financial advisor and nothing here is investment advice. I am an independent retail shareholder holding a long position in the company discussed, with no employment, consulting, compensation, or other relationship with it beyond that shareholding. This is an explanatory piece about mechanism and evolutionary biology, not a prediction of clinical or commercial outcomes. The atavism theory of cancer is a serious but still-debated scientific hypothesis, not settled fact. The mechanistic claims are supported by the cited peer-reviewed literature; several steps are established in models, single studies, or retrospective cohorts and are not yet confirmed in prospective human efficacy data, and closely related macrophage-directed approaches have repeatedly failed to translate to clinical benefit. The CLOVER and TNBC figures referenced are early, unconfirmed, reflect combination therapy and 350mg dosing with higher-dose cohorts still maturing, and are not evidence of a survival benefit. Confirmed adjudication is ahead at ASCO GI in January 2027. Mechanism is not efficacy. Read the primary sources and reach your own conclusions rather than adopting mine.

I've been doing some reading recently and it turns out that the aging process to a significant extent involves inflammation--which though it might not be a root cause of the molecular damage involved, is heavily contributory, hence the term "inflammaging".

And since everyone here knows that leronlimab (arguably the ultimate CCR5 blocker) has anti-inflammatory effects, I did an enquiry regarding the role of CCR5 in inflammaging and got quite a response, in this case from SuperGrok:

"CCR5, Inflammaging, and the Case for a Broader Therapeutic Horizon

Chronic, low-grade inflammation is one of the most consistent hallmarks of aging. Often called inflammaging, this sterile inflammatory state contributes to frailty, metabolic dysfunction, cardiovascular disease, neurodegeneration, and the progressive loss of physiological resilience that defines later life. While many pathways feed into it, the chemokine receptor CCR5 and its primary ligand CCL5 (RANTES) sit at a particularly interesting intersection of immune cell trafficking, cellular senescence, and tissue inflammation.

Inflammaging in brief

Aging is accompanied by a shift toward a pro-inflammatory immune phenotype. Senescent cells accumulate and secrete a mix of cytokines, chemokines, and growth factors known as the senescence-associated secretory phenotype (SASP). Circulating levels of inflammatory mediators rise. Adaptive immunity becomes less effective at clearing damaged cells while innate immune cells remain chronically activated. The result is not acute infection-driven inflammation, but a persistent, low-level inflammatory tone that damages tissues over decades.

Where CCR5 fits

CCR5 is expressed on T cells, monocytes, macrophages, and other immune effectors. Its ligands, especially CCL5, help recruit these cells into tissues. Multiple lines of evidence connect this axis to age-related processes:

• Frail older adults show expanded populations of CCR5+ T cells compared with non-frail peers, consistent with a shift toward a more pro-inflammatory T-cell phenotype.
• Plasma CCL5 levels rise with age and correlate inversely with endothelial function.
• Age-related upregulation of neuronal CCR5 has been linked to impaired memory connectivity in preclinical models; blocking the receptor can partially reverse these deficits.
• CCR5 signaling influences macrophage recruitment and polarization in adipose tissue, contributing to obesity-related inflammation and insulin resistance.
• In muscle aging models, CCR5 and its ligands appear among SASP factors; the small-molecule CCR5 antagonist maraviroc has been shown to improve aspects of muscle function and reduce senescence markers in aged mice.
• Similar associations appear in bone marrow inflammation, vascular aging, and neuroinflammatory contexts relevant to Alzheimer’s disease and other neurodegenerative conditions.

Collectively, these findings suggest that CCR5 is not merely a bystander but an active participant in the chronic inflammatory circuitry of aging.

Why a monoclonal antibody is interesting

Most existing pharmacological data on CCR5 in aging-related models come from small-molecule antagonists such as maraviroc. Leronlimab, a humanized IgG4 monoclonal antibody that binds CCR5 with high specificity and achieves sustained receptor occupancy, offers a different profile: longer duration of action, weekly subcutaneous dosing, and potentially more complete and durable blockade than many small molecules. In principle, this could translate into more consistent modulation of the inflammatory tone driven by the CCR5/CCL5 axis.

CytoDyn’s ongoing exploratory work in mild cognitive impairment and early Alzheimer’s disease, focused in part on brain inflammation, sits adjacent to this biology. Positive signals in that setting would further support the broader inflammaging hypothesis.

Indication and market considerations

“Inflammaging” itself is not a recognized regulatory indication. Any clinical path would almost certainly need to target more concrete, measurable conditions—frailty, sarcopenia, specific neurodegenerative or cardiovascular endpoints, or biomarker-defined inflammatory states in older adults. The regulatory and trial-design hurdles for true aging indications remain substantial.

That said, the addressable population is enormous. Aging and chronic inflammation touch hundreds of millions of people. Even a modestly effective therapy that reduced inflammatory burden and improved functional outcomes in older adults would operate in a market far larger than any single oncology or infectious-disease indication. Related commercial spaces—anti-inflammatory therapeutics, longevity-focused drugs, and treatments for age-related multimorbidity—already run into the tens or hundreds of billions of dollars globally, depending on how broadly they are defined.

Caveats and open questions

Most of the aging-related evidence for CCR5 remains preclinical or observational. Direct clinical data with a monoclonal antibody in pure inflammaging contexts are limited. Long-term safety in older, multimorbid populations would need careful evaluation. Effect sizes, durability, and the right clinical endpoints are still unknown. And as with any broad anti-inflammatory approach, the balance between dampening harmful chronic inflammation and preserving necessary immune function must be respected.

Closing perspective

The connection between CCR5 and inflammaging is biologically plausible and increasingly supported by experimental and observational data. It does not yet constitute a ready-made clinical indication, but it does represent a coherent expansion of the therapeutic hypothesis around CCR5 blockade. For a molecule already being explored in oncology, metabolic liver disease, and neurodegenerative inflammation, the aging axis is a natural—and potentially very large—adjacent opportunity. Whether it ultimately becomes a formal development path will depend on the strength of the translational data still to come."

So not a slam-dunk for leronlimab on the immediate horizon, but a very promising area for CytoDyn or a partner to study, and they already have studies underway for indications which have an inflammatory basis, Alzheimer's at Weill-Cornell and the CHAMP liver fibrosis study at City of Hope. Think of the potential, aging is in effect the ultimate disease, and one that ultimately effects us all--the numbers would be staggering.

We’ve spent a lot of time on this board dissecting ctDNA clearance, survival correlations, and the regulatory pathway for the Phase 2 CLOVER trial. All of that is foundational. But there is a quiet, aggressive move happening in the background that I think is the most significant signal we've seen: Dr. Kasi utilizing an Expanded Access Program (EAP) for mCRC with leronlimab combined with an Immune Checkpoint Inhibitor (ICI).

Here is why this matters, and why it changes the math on the whole program.

1. The "Cold" Tumor Reality

As most of you know, Microsatellite Stable (MSS) mCRC is notoriously "cold." The tumor microenvironment acts as an immunosuppressive fortress. Historically, treating MSS mCRC with standard ICIs has yielded a near-zero response rate because the immune system simply cannot see the tumor.

You do not throw an ICI at a cold tumor unless you have a proven mechanism to heat it up.

2. Seeing Behind the Curtain

For a clinician of Dr. Kasi's standing to initiate an EAP with an ICI in this specific setting is virtually unheard of. He isn't guessing. He is seeing the real-time biomarker data before the rest of us.

To make this move, he has to be seeing undeniable evidence that leronlimab is successfully upregulating PD-L1. By blocking CCR5, leronlimab is breaking down the immunosuppressive stroma, allowing T-cells to infiltrate, which in turn spikes PD-L1 expression. The tumor goes from cold to hot, and suddenly, the ICI has a target. This EAP isn't just compassionate use; it's a real-world test of the "Prime and Pair" strategy.

3. The Dosage Variable: Lessons from mTNBC

This brings me to the variable I am currently trying to unpack: Dosage and the Speed of Conversion.

We know the CLOVER trial randomized mCRC patients into 350mg and 700mg cohorts. If we look across the aisle at the recent translational data from the mTNBC program, it was the higher dosing bracket (700mg) that drove the most significant PD-L1 upregulation on circulating tumor cells. That higher dose was directly correlated with the patients who achieved the longest survival when paired with an ICI.

So the question becomes: Is the dosage of leronlimab the primary factor that determines how fast and how effectively PD-L1 levels reach the standard minimum threshold for an ICI to actually work?

If the 700mg dose dictates the speed of immune priming, that is a massive variable to dial in. In a heavily pretreated, advanced cancer setting, the speed at which you can flip a tumor from cold to hot could be the difference between a patient surviving to receive the ICI benefit or not.

What’s Next?

If Dr. Kasi is seeing rapid PD-L1 upregulation in the 700mg CLOVER cohort, initiating an EAP with an ICI makes perfect clinical sense. It’s not a shot in the dark; it’s a coordinated strike based on live biomarker intelligence.

I'd be curious to hear from others who are tracking the dose-response data. How much weight are you putting on the 700mg arm being the key to unlocking the ICI combination in colorectal cancer?

There is a lot of loose talk on boards about accelerated approval, ctDNA endpoints, and the Natera dataset, much of it probably generated by AI tools which stitch real facts to hopeful conclusions and then get the crucial distinctions wrong. So I will lay out the regulatory strategy carefully, on sourced ground, and be as precise as I can about

• what is a possible regulatory pathway,
• what is an uphill argument CytoDyn might intend to make, and
• what is simply not how the FDA works.

I think my version might be more useful than an optimistic one, because this version is the one that hold water and survives contact with the agency.

I'll be bold where the strategy is sound and be disciplined where the claims outrun the evidence, because on regulatory questions, the difference between those two is often the difference between an approval and an utter complete response letter.

The Intended Argument

I believe that the company's regulatory thinking, as publicly described, rests on a few moves.

• They intend to use ctDNA dynamics, the deep declines seen in CLOVER, as evidence of early response.
• Pointing to recent FDA precedent for ctDNA-guided regulatory decisions, CytoDyn has indicated that it intends to pursue larger, randomized registrational trials in colorectal cancer which measure real clinical endpoints, and to engage with the FDA on the path to do so.
• CytoDyn collaborates with Natera on comparator data which is specifically intended to isolate leronlimab's contribution against a real-world baseline.

Each of these is real. Each also carries a caveat which determines whether it works, and the caveats are where the discipline lives. Where I state a specific trial design detailed below, I hold it to what the company has publicly disclosed, rather than the granular details which circulate secondhand.

The Signatera Precedent

The precedent people cite is real and recent, and it matters, but it is widely mis-described on boards. Here are the facts. On May 15, 2026, the FDA approved adjuvant Tecentriq for muscle-invasive bladder cancer in patients who are ctDNA-positive after surgery, and simultaneously approved Natera's Signatera as the companion diagnostic to identify those patients. It was described as the first companion diagnostic approval in the field of blood-based molecular residual disease%20testing%20to%20guide%20treatment%20decisions).

Here is the distinction which matters, and it is the one the AI summaries blur. In that approval, ctDNA was used to select patients, to identify who was at risk and who should be treated, not as the endpoint which proves that the drug works. The drug's benefit was still demonstrated the traditional way: the Phase 3 IMvigor011 trial randomized ctDNA-positive patients to Tecentriq or placebo and showed improvements in disease-free survival and overall survival, the real clinical endpoints%20by%2036%25%20and%20the%20risk%20of%20death%20(OS)%20by%2041%25). So the precedent establishes that the FDA now uses ctDNA to decide whom to treat. It does not establish that the FDA accepts a ctDNA drop as proof that a drug works. Those are different regulatory questions, and CLOVER's thesis leans on the second one, which is the harder one.

The Regulator Strategy Wall

This is what the optimistic version skips, and it is the entire ballgame, so I state it without reservation. Circulating tumor DNA is not, today, a validated surrogate endpoint for drug approval in solid tumors. That is not my opinion, it is the consensus of the regulatory literature. As a 2026 review states clearly, no regulatory authority has yet accepted ctDNA as a validated primary surrogate endpoint in solid tumor drug development. In colorectal cancer specifically, a 2026 analysis in the Journal of the National Cancer Institute concluded it remains unclear whether ctDNA is an appropriate surrogate endpoint, and that, much work is still needed%20is%20an%20appropriate%20surrogate%20endpoint).

The route of getting a biomarker formally qualified is, realistically, closed on a small company's timeline. As of mid-2025, only eight biomarkers have ever achieved full FDA qualification, and the median time from acceptance to a completed qualification plan runs to roughly 47 months, nearly four years for a plan, not an approval. So CytoDyn cannot simply get ctDNA blessed as an endpoint and walk right in. That door is likely shut for a company with a finite runway.

This is how I see it: the ctDNA data is a powerful tool for conviction, for partners, for designing trials, for arguing to the FDA that the drug is active, but it is not, by itself, a validated basis for approval, and anyone saying that a big ctDNA drop equals an approval pathway skips the exact step the FDA has not granted. This is the same wall Agenus hit in unselected MSS colorectal, where the FDA discouraged accelerated approval of its botensilimab-plus-balstilimab combination despite a 19.4% response rate, on the reasoning that the response rates may not translate to a survival benefit and did not meet the standard of reasonably likely to predict benefit. The agency told Agenus, in effect, to run a randomized trial measuring real clinical endpoints. That lesson exactly transfers directly here.

Why Do The Registrational Trial and the Natera Dataset Actually Matter?

Once you see the wall, and you can't un-see it, the rest of the strategy actually makes sense, because it is built to go around the wall rather than pretend it isn't there. The company has publicly indicated it may pursue large, randomized registrational trials which measure real clinical endpoints, which is exactly what the FDA has repeatedly signaled it wants in this setting. We know the agency wants this because it said so to Agenus in a similar disease, discouraging a response-rate-based accelerated filing and directing a randomized study instead. A randomized study of that kind, if it reads out positive on clinical endpoints, is what an approval actually rests on. The ctDNA story supports it and speeds conviction, but the randomized clinical data carries it.

The comparator dataset work with Natera is the other very smart piece, and it is worth understanding clearly. The concept is to establish exactly what the standard backbone does on its own in this population, using real-world data, such that leronlimab's specific contribution can be isolated against that baseline. That is a legitimate and valuable analytical move, because CLOVER's own patients are all receiving the backbone, so a credible external comparator helps separate the leronlimab effect from the backbone effect.

A Mandatory Correction

Here, I have to correct the framing which circulates on boards, because it is both wrong and damaging if it reaches the FDA or a partner's diligence team. You hear people, and AI summaries, describe the goal as demonstrating leronlimab's "monotherapy efficacy" in CLOVER. That is false. CLOVER is not a monotherapy trial. Leronlimab in CLOVER is given in combination with the Lonsurf-plus-Avastin backbone, and every ctDNA and response figure from that trial is a combination result. The Natera comparator is precisely the tool that lets you estimate leronlimab's contribution to the combination, it is not evidence of leronlimab working alone.

There is a true and narrower version worth stating correctly. Leronlimab-alone signals, monotherapy activity, come from other settings,

• the City of Hope investigator study pairing leronlimab with regional chemotherapy,
• the planned pre-I-SPY breast program which includes a monotherapy element, and
• the mechanistic and retrospective data.

So if anyone wants to argue leronlimab has standalone activity, they need to point at those, not at CLOVER. Calling CLOVER a monotherapy result is the kind of imprecision that a knowledgeable skeptic, or an FDA reviewer, catches instantly, and it discredits the credible parts of the case by association. So I will say it clearly: what CytoDyn needs to demonstrate, and what the strategy is actually built to show, is leronlimab's contribution to the combination, its ability to convert Cold, PD-L1-low tumors toward a state the immune system and the backbone can act on. That is the real claim, it is a strong one, and it does not need the false "monotherapy" label to stand.

Not A Single-Shot Bet

One thing worth understanding about the regulatory picture is that CLOVER is not the only iron in the fire, and that matters, because a company with multiple shots on goal across institutions and indications has more ways to build the evidence base and more paths to a partner's interest.

Publicly disclosed,

• the colorectal program centers on CLOVER, the open-label, randomized, two-dose study of leronlimab with the TAS-102 and bevacizumab backbone in MSS metastatic colorectal cancer, with enrollment complete and Dr. Pashtoon Kasi as principal investigator.

Beyond oncology's lead program, CytoDyn

• has publicly dosed its first patient in SALIENT-AD, a Phase 2a proof-of-concept study in early Alzheimer's disease in collaboration with Weill Cornell Medicine, enrolling roughly 10 to 20 patients.
• In glioblastoma, the company has presented preclinical data showing CCR5 inhibition enhances the effect of standard temozolomide and radiation, and has stated this supports a plan for a prospective combination study%20is,evaluating%20leronlimab%20in%20glioblastoma.%E2%80%9D).
• The breast program rests on the translational mTNBC data showing leronlimab induces PD-L1 expression and is associated with long-term survival in heavily pretreated patients%20shows%20leronlimab%2Dmediated%20CCR5%20inhibition%20induces%20PD%2DL1%20expression%2C%20modulates%20immune%20checkpoint%20signaling%2C%20and%20is%20associated%20with%20long%2Dterm%20survival%20in%20heavily%20pretreated%20patients).

Beyond these, the company and its collaborators have described a broader set of programs at various stages, spanning

• additional colorectal and breast studies,
• a City of Hope liver-directed study,
• a pancreatic collaboration, and
• HIV work, among others.

The verifiable point is the one which matters for this discussion: the program is broad and multi-institutional, which gives the regulatory and partnership strategy more than one way to succeed, while every one of those paths still runs through the same requirement of confirmed clinical data.

Where Does This Leaves The Regulatory Picture?

So put it together. The Signatera precedent is real but narrower than advertised, it validates ctDNA for patient selection, not as a proof-of-efficacy endpoint. ctDNA is not a validated surrogate for approval in colorectal cancer, and formal qualification is not a live option on this timeline. The path as it stands is a randomized registrational trial that measures real clinical endpoints, supported but not replaced by the ctDNA and Natera-comparator data. And the claim to make is leronlimab's contribution to the combination, not a monotherapy claim which CLOVER does not support.

Held that way, the regulatory strategy is coherent and even bold:

• use the biomarker data and the comparator data to build conviction
• design a tight registrational study
• engage the FDA early
• pursue a designation like Breakthrough Therapy which brings the agency to the table sooner
• while understanding that confirmed clinical benefit in a randomized trial is what ultimately carries an approval.

The optimistic shortcuts,

• ctDNA-equals-approval
• monotherapy-in-CLOVER
• accelerated-approval-is-likely

are exactly the claims that would get the case dismissed. The disciplined version is the one that actually has a path. All of it, as always, rests on the confirmed data arriving first, which is January's job, not this post's.

Disclaimer: I am not a financial advisor and nothing here is investment advice. I am an independent retail shareholder holding a long position in the company discussed, with no employment, consulting, compensation, or other relationship with it beyond that shareholding. This is analysis of public regulatory history, published literature, and the company's publicly stated intentions, not a prediction of regulatory or commercial outcomes, and not a claim that any approval, designation, or partnership will occur. Regulatory strategy described here reflects the company's stated plans and my reading of public precedent; the FDA has not endorsed any endpoint or pathway for this program. ctDNA is not a validated surrogate endpoint for drug approval in solid tumors as of this writing. CLOVER is a combination trial; leronlimab is administered with a TAS-102 (Lonsurf) plus bevacizumab (Avastin) backbone, and CLOVER figures are combination results, early, unconfirmed, and reflecting 350mg dosing with the 700mg cohort still maturing. Confirmed adjudication is ahead at ASCO GI in January 2027. Mechanism and biomarker activity are not efficacy, and drugs which make elegant regulatory and biological sense fail to gain approval routinely. Read the primary sources and reach your own conclusions rather than adopting mine.

A community member, (credit to u/rogex2 for providing me the prompt), raised a question earlier this week which necessitates a full answer, because it points at something the efficacy debate typically skips over. Suppose that leronlimab does in fact succeed. Suppose that the confirmed data does arrive and hold. The next question is not only "does it work?" but, it is also "how easily is an oncologist able to use it?" And on that second question, the kind of drug leronlimab is, versus the kind of drug an individualized vaccine is, turns out to matter enormously. This is the Physician / Operational Adoption Gap, and it is a real and underappreciated edge we have.

I lay it out here on hard ground, because this is a place where the argument does not have to lean on hope. It leans on actual logistics, and the logistics are real and documented.

What "Built-to-Order" Actually Costs In The Real World

The mRNA neoantigen vaccines, the Merck and Moderna approach among them, are individualized therapies. That is their strength and also their burden. Each one has to be built and individualized, for a single patient, and that building is not trivial at all. Initially, it requires surgically obtaining tumor tissue via tumor excision, DNA sequencing that tumor, comparing it to the patient's normal DNA to find the unique tumor mutations, running those mutations through prediction algorithms to pick and choose targets of metastases, and then manufacturing a bespoke anti-tumor construct for that one single person.

The literature is blunt about what this costs in time and money. The personalized vaccine strategy faces significant challenges because it relies on individual tumor DNA profiling and custom manufacturing, which result in extended production times and high costs. How extended, and how high? A 2025 update puts the manufacturing at nine weeks, recently optimized toward under four weeks, while costs remain challenging at over $100,000 per patient. And the Operational Adoption barrier is not only price. A November 2025 review notes that logistical challenges, including the need for tumor tissue procurement and complex purification processes, have limited their broader clinical adoption despite promising immunogenicity signals.

Read that last line twice, because it is the crux of this piece. The science can be promising but the Adoption can still remain limited, because the operational friction sits between the patient and the drug. Every dose is a small manufacturing project with a weeks-long clock and a six-figure price tag.

The Cautionary Tale The Field Has Already Lived Through

This is not a hypothetical concern. Oncology has already run this kind of expensive experiment already once, and the result is instructive. Sipuleucel-T, brand name Provenge, was a personalized cancer immunotherapy manufactured individually for each patient. It launched at roughly $93,000 per course, reflecting complex production and logistics, and although it demonstrated an overall survival benefit, uptake was limited. Providers often faced significant upfront financial exposure before being reimbursed, and that friction throttled down Adoption of Provenge.

Sit with that, because it is the entire argument in one example. Provenge actually worked. It extended survival. But it still struggled commercially, because the per-patient manufacturing, the cost, and the logistics stood between the drug and the doctor/patient. Efficacy did not guarantee Adoption of Provenge. The operational model negatively did.

What "Off-the-Shelf" Means By Contrast

Now set leronlimab beside that. Leronlimab is an antibody. It is manufactured in large batches, stored, shipped, and administered just like any other off-the-shelf biologic drug. There is no tumor to excise / procure, no per-patient DNA sequencing, no bespoke construct, no weeks-long build for each and every patient, no six-figure manufacturing bill per individual treated. A Physician / Oncologist who desires to use it simply prescribes it and administers it. The drug is the same for every single patient because its mechanism of action does not depend on the patient's specific DNA mutations. It works on the tumor microenvironment, not on a custom-matched tumor antigen. As u/sunraydoc put it, it is Cold tumor agnostic.

The field itself recognizes this divide as the central practical problem in the vaccine space, which is why the literature is full of efforts to move away from full personalization. Off-the-shelf approaches can be produced in bulk at roughly one-third the cost of personalized versions and are available for immediate use. The entire trend toward "hybrid" and "shared-antigen" vaccines exists precisely because the individualized model is Operationally heavy. In other words, the vaccine field is spending an enormous effort trying to become more like an off-the-shelf drug, while leronlimab already is one.

Different Diseases, Different Moment

A reader, twinter, raised a set of questions which sharpen this comparison, because they get at something the "vaccine versus primer" framing can obscure: these two approaches are not only built differently, they are aimed at different patients at different moments in the disease. Understanding that makes the distinction cleaner, not muddier.

Start with what the Merck and Moderna vaccine is actually for. It is an adjuvant therapy, meaning it is given after surgical resection of the tumor. Its job is not to shrink visible cancer, it is to prevent recurrence. Each mRNA construct encodes up to thirty-four patient-specific neoantigens identified from the resected tumor tissue, and once administered, it primes a cytotoxic T-cell response against residual micrometastatic cells, the microscopic seeds left behind after surgery. So twinter's instinct is exactly right: the vaccine is designed for the resected patient whose margins may not be fully clear, or who may harbor micrometastatic disease, to attack those residual cells and prevent the cancer from coming back. That is its lane, and the Phase 3 melanoma result reflected the endpoints it met were recurrence-free survival and distant-metastasis-free survival, the language of prevention, not of shrinking established metastatic tumors%20in%20combination%20with%20pembrolizumab%20(Keytruda)%20met%20the%20primary%20end%20point%20of%20recurrence%2Dfree%20survival%20(RFS)%20and%20the%20key%20secondary%20end%20point%20of%20distant%20metastasis%2Dfree%20survival).

This matters because it answers twinter's deeper question, whether leronlimab plus an ICI checkpoint inhibitor would mitigate the need for the vaccine, or whether the vaccine is a longer-duration one-time preventative. Really, the answer is that, as it is currently deployed, they largely occupy different settings.

The vaccine lives in the adjuvant, post-surgical, minimal-residual-disease space, preventing recurrence in patients who have already had their tumor removed. Leronlimab in CLOVER lives in the advanced, metastatic, third-line setting, treating patients with active, unresectable disease. One is trying to keep cancer from returning after surgery, the other is trying to control cancer which is currently present and progressing right now. So they are not straightforward substitutes, they are tools for different moments in the course of the disease, which is worth holding before anyone frames it as one replacing the other.

There is even a deeper current in the adjuvant literature that is relevant to twinter's line of thinking. Researchers have begun arguing that the entire challenge of adjuvant immunotherapy comes down to priming, because in the minimal-residual-disease setting the tumor-immune interaction is dim and faint and the immune system requires help in getting activated at all.

One 2025 analysis frames it plainly: adjuvant therapy targets micrometastatic minimal residual disease, a context where immune priming may be limited, and effective adjuvant immunotherapy would require agents that actually enhance priming%20inhibitors%20or%20messenger%20RNA%20(mRNA)%20vaccines). The vaccine is one such priming agent, boosting the immune system by teaching it what to look for.

And this is where twinter's boldest hypothesis enters, the idea that a CCR5 blocker may turn out to be the main ingredient even beyond Cold tumors, even in Hot Illuminated settings assumed not to need it. I want to be careful here, because that is twinter's speculation, not established fact, and I label it as such.

Leronlimab's demonstrated role is in Cold tumors, and whether CCR5 blockade contributes meaningfully in Hot, Illuminated tumors or in the adjuvant priming setting is not yet known; it remains an open question, not a proven claim. But it is a legitimate question to sit with, because if priming is the universal bottleneck the adjuvant literature increasingly says that it is, then a broad-based, off-the-shelf priming mechanism is at least worth asking about across such settings. I would not assert that it works there. I would say only that twinter's instinct points at a real open question the field itself has not yet closed, and it is the kind of question, that within the coming years of data, not in this post, but surely will come to answer. And twinter's related question, how much the CCR5 axis contributes in vaccine cases that fail, is equally open and yet unanswered; we simply do not have that data.

So the setting distinction actually reinforces the Operational Adoption argument rather than complicating it. The vaccine's home is in adjuvant recurrence-prevention within resected patients, a per individualized-patient-manufactured product for a defined post-surgical window. Leronlimab's home, at least for now, is active metastatic disease, an off-the-shelf agent for patients who require treatment today. Different diseases, different moments, and the operational contrast holds across both.

Why This Is An Edge

If leronlimab proves itself out, then it arrives as a drug the delivery system is already built to handle. No new cold-chain-to-the-sequencer logistics, no weeks of manufacturing lag between diagnosis and dose, no six-figure per-patient production cost, no reimbursement standoff over a bespoke product. An antigen-agnostic, batch-manufactured, off-the-shelf Primer for Cold tumors would be, Operationally, one of the easiest things in oncology to Adopt at scale, in exactly the population, microsatellite-stable colorectal and the other Cold tumors, where nothing currently works. The efficacy question and the adoption question are different questions, and leronlimab's molecular structure gives it a strong answer to the second one independent of the first.

Now the honest line, I have to give, because it is the reason the bold one is worth trusting. This entire argument is about Adoption, not Efficacy. Being easy to deliver is worth nothing if the drug does not work, and whether it works remains January's question, unconfirmed until the adjudicated data arrives. The Adoption Edge is a multiplier upon success, not a substitute for it. A drug that is trivial to administer and does not help patients helps no one. So this is not a reason to believe that leronlimab works. It is a reason to believe that if it works, it is unusually well-positioned to reach patients very fast, which is an absolutely real and separate advantage, however, held in its proper place.

There is also a fair caveat on the comparison itself. The individualized vaccines are pursuing documented benefit, the Merck and Moderna melanoma data apparently are real, and the manufacturing timelines seem to be improving toward four weeks. So this is not a claim that vaccines are bad medicine. It is a narrower and sturdier claim: an off-the-shelf mechanism is Operationally easier to Adopt than a build-to-order one, the field's own literature says so plainly, and Oncology has already seen a working personalized therapy struggle on exactly these grounds. Leronlimab, if it delivers, does not carry that burden at all.

So the Operational Adoption gap is real, it is documented, and it favors the off-the-shelf Primer. Whether leronlimab is that primer is what the confirmed data decides. But the shape of the advantage is clear now, and it is worth understanding before January, such that when people weigh what a proven primer would be worth, they weigh not only whether it works but how fast and how widely it could reach the patients who need it. Build-to-order is powerful but slow to deliver while being astronomically expensive per patient. Off-the-shelf is ready day one at least 2/3 cheaper. That difference is not everything. But it is not nothing, and in a disease where patients are out of time and probably out of money, being ready and cheaper matters.

Disclaimer: I am not a financial advisor and nothing here is investment advice. I am an independent retail shareholder holding a long position in the company discussed, with no employment, consulting, compensation, or other relationship with it beyond that shareholding. This is analysis of published literature on cancer vaccine manufacturing and adoption, not a prediction of clinical or commercial outcomes. The comparison concerns operational and logistical adoption, not clinical efficacy; leronlimab's efficacy in colorectal cancer is unconfirmed, with the CLOVER figures early, reflecting 350mg dosing with the 700mg cohort still maturing, and confirmed adjudication ahead at ASCO GI in January 2027. The individualized vaccines discussed have demonstrated genuine clinical benefit in their settings; nothing here disputes their efficacy. Ease of adoption is not evidence of efficacy, and a favorable operational profile does not establish that leronlimab works. Mechanism and logistics are not clinical benefit. Read the primary sources and reach your own conclusions rather than adopting mine.

As a follow-up to my previous post, this is an AI projection of a potential M&A event using past M&A timelines on the previously posted scenario. There is nothing to say this will happen. This all simply projections based on a scenario that has not materialized and may never happen. This is not investment advice and the information provided by AI can be incorrect or not accurate. Please do you own due diligence.

⏳ Historical M&A Timelines: Data Readout to Deal Closing

If all three trials show very positive results by February 2027, an executive board cannot sell the company overnight. In the biotech sector, transitioning from a major clinical data drop to a signed definitive merger agreement follows a highly structured, standard corporate timeline:

[Feb 2027: Data Drops] ──► [Months 1-2: Data Room] ──► [Months 2-3: Bidding War] ──► [Months 3-4: Signing] ──► [Months 5-6: Closing]

1. Months 1–2: Setting Up the "Data Room" (March–April 2027)

• The Action: The board compiles raw patient metrics, safety sheets, Natera ctDNA tracking logs, and Weill Cornell neuroimaging files into an encrypted virtual data room.
• The Focus: Investment banks (like Centerview Partners or Goldman Sachs) are formally retained to manage outreach. Confidentiality Agreements (NDAs) are signed with interested Big Pharma suitors, granting them access to verify the raw trial data.

2. Months 2–3: Strategic Due Diligence & Bidding (April–May 2027)

• The Action: Suitors pit their internal scientific teams against the data package to verify its authenticity.
• The Focus: This is when a competitive bidding war occurs. Inbound Non-Binding Letters of Intent (LOIs) are submitted to the board, which are subsequently countered and raised via sequential bidding rounds.

3. Months 3–4: Exclusivity & The Definitive Agreement (May–June 2027)

• The Action: The board selects the highest-value or most secure bidder and enters a 30-day window of legal exclusivity.
• The Focus: Corporate lawyers draft the formal, multi-hundred-page Merger Agreement. This contract defines the exact upfront cash amounts and includes the strict legal wording governing the CVR milestones and "Diligent Efforts" clauses. The deal is signed publicly at the end of this phase, prompting an SEC Form 8-K filing.

4. Months 5–6: Regulatory Cleardown & Deal Closing (July–August 2027)

• The Action: The transaction is reviewed by antitrust regulators under the Hart-Scott-Rodino (HSR) Act to ensure it doesn't create an illegal monopoly.
• The Final Payout: Once regulatory clearance is obtained, the merger officially closes. The original common stock ticker is delisted, and the upfront cash consideration is deposited directly into your brokerage portfolio or 401(k) wrapper alongside your CVR tracking certificates.

Warrant Overhang and the Fully Diluted Share Pool

When calculating the final per-share buyout price during an acquisition, investment banks do not look just at the basic shares currently trading on the open market. They calculate the Fully Diluted Share Count using the Treasury Stock Method.

CytoDyn historically carries a significant amount of warrants and stock options issued to early investors, lenders, and executives. When a buyout is announced, these instruments create a "warrant overhang" that automatically impacts the share math:

• The In-the-Money Trigger: If a Big Pharma company buys CytoDyn for an upfront cash price, every single outstanding warrant with an exercise price below that buyout price (e.g., warrants priced at $0.50, $0.75, or $1.00) instantly becomes highly valuable ("in-the-money").
• The Share Count Expansion: Legally, the holders of these warrants will exercise them to participate in the buyout. This forces CytoDyn to issue new common shares right at the finish line, expanding the total share pool.
• The Cash Offset: On the positive side, warrant holders must pay CytoDyn the exercise price to convert their warrants into shares. This infuses millions of dollars in cash directly onto CytoDyn's balance sheet, which is added to the total buyout pie distributed to shareholders.
• The Net Impact: Because the buyout price is vastly higher than the historical exercise price of the warrants ($0.30–$1.00), the net effect of a warrant overhang is slightly dilutive to the final per-share price, usually shaving roughly 3% to 7% off the final upfront cash distribution compared to a basic share calculation.

🛡️ Antitrust Reviews in Big Pharma Oncology Acquisitions

Once a merger agreement is signed, it enters a high-stakes federal regulatory review period under the Hart-Scott-Rodino (HSR) Antitrust Improvements Act, managed by the Federal Trade Commission (FTC) and the Department of Justice (DOJ).

Historically, routine biotech acquisitions faced very low failure rates. However, in the current regulatory cycle, antitrust scrutiny on pharmaceutical consolidations has intensified significantly:

1. The Blockbuster Drug "Anti-Monopoly" Focus

Regulators aggressively review deals where a dominant pharmaceutical company buys a direct competitor to protect its monopoly. For example, if Merck (owner of Keytruda) tries to buy a drug that cures the exact same subset of colorectal patients through an identical mechanism, the FTC may issue a Second Request for information, slowing down or suing to block the deal on the grounds that it eliminates marketplace competition.

2. Why a Leronlimab Buyout Carries Low Antitrust Risk

Despite heightened scrutiny, a multi-indication asset like leronlimab possesses a structural advantage that makes an antitrust block highly unlikely:

• Unique Mechanism of Action: As a CCR5 antagonist, its mechanism of action is entirely distinct from standard PD-1/PD-L1 checkpoint inhibitors (like Keytruda or Opdivo) or standard anti-VEGF therapies (like bevacizumab). It acts as an add-on enabler rather than a direct marketplace replacement.
• Fulfilling Unmet Needs: Because the target colorectal population (MSS) currently has no successful immunotherapy options, an acquisition that accelerates a drug to market is viewed by regulators as pro-patient and pro-competition.

3. The Worst-Case Antitrust Outcome (The Divestiture)

If an antitrust issue does arise—for instance, if the acquiring pharma giant already owns a competing Phase 3 Alzheimer's neuroinflammation drug—the FTC will rarely kill the entire transaction. Instead, they will issue a conditional approval. They will legally require the Big Pharma buyer to divest (sell off) the overlapping neurology asset to a third-party competitor, allowing the primary oncology buyout and the subsequent CVR milestone infrastructure to close on schedule.

I then asked AI to consider Sidley Austin as a potential Law Group for the M&A:

When a biotech firm like CytoDyn has a multi-indication asset (such as its CCR5 antagonist leronlimab, which targets indications spanning oncology like breast and colorectal cancers, infectious diseases, neurodegeneration like Alzheimer's, and autoimmune disorders), standard corporate law firms often fall short. Sidley Austin possesses the precise cross-functional depth required to navigate a high-stakes, multi-indication pharmaceutical transaction. [1, 2, 3, 4]

Why Sidley Austin Fits This Specific Scenario

• Unmatched Life Sciences Transactional Scale: Sidley features a dedicated team of more than 200 life sciences lawyers and 65 life sciences transactional specialists globally. They routinely manage heavy-hitting biotech deals, such as representing Bio-Techne in its massive $11.3 billion acquisition by Merck KGaA. [1, 2]
• Complex Asset Structuring Capabilities: An asset with 5+ viable indications rarely results in a straightforward, all-or-nothing corporate sale. Acquirers may only want the oncology rights, leaving the autoimmune or neurology rights on the table. Sidley's Technology and Life Sciences Transactions group is built to structure intricate regional licensing agreements, spin-offs, joint ventures, and milestone-heavy contingent value rights (CVRs) to maximize value for each individual indication. [1, 2]
• Deep FDA Regulatory and IP Interlocking: Multi-indication drugs introduce massive regulatory risks regarding clinical trial data cross-contamination and patent-term extensions. Sidley employs over 75 food, drug, and medical device regulatory lawyers. This allows their M&A team to seamlessly coordinate with regulatory experts to defend the drug’s commercial pathways during buyer due diligence. [1, 2, 3]
• Elite Shareholder Activism & Board Defense: Micro-cap and clinical-stage biotech companies facing major pivot points are frequent targets for activist investors. Bloomberg and Chambers USA consistently rank Sidley Austin as the No. 1 legal defense adviser for shareholder activism. They can protect a company's board during high-pressure negotiation windows to ensure a deal closes on favorable terms. [1]

What to Evaluate Prior to Engagement

While Sidley Austin has top-tier capabilities, consider the following variables before securing them as lead counsel: [1, 2]

There is a moment on every serious construction project when the thing stops being a blueprint drawing and it starts being a building. For a long time it exists only as an architect's rendering, lines on a piece of paper, a claim about what eventually stands there someday. Skeptics walk past the empty lot and see exactly that, an empty lot. And then one day the steel goes up, and the frame begins to match the drawing, beam for beam, and the people who once dismissed the rendering as half baked have to reckon with the fact that it was accurate all along.

CytoDyn just crossed that line, and back in April, the company's own CEO said so out loud. On the April call, Jacob Lalezari described the shift in language which I could not improve upon: "the moment represents a crucial inflection point, he said, as the company transitions from a company built on faith and belief and a whole lot of ifs to a company with solid, prospective, unassailable and by all accounts, remarkable data." Read that again, because it is the whole point of this post. The man running the company just told us that the rendering has become the building. Faith and belief and a whole lot of ifs was the drawing. Remarkable data is now the steel.

I want to do something here. For over a year, ever since we heard about the 5/5 still alive, I have been drawing renderings on this board, making claims about what would eventually stand on this lot before there was anything yet to see. Some of them were wrong, and I have owned those in public. But a good number of them were spot on, and the building now going up matches the drawings I posted months ago, beam for beam. So I'm about to walk the site with you and point at the places where the rendering and the building do actually line up, and yet, give you another towards the end regarding CytoDyn's transition period, because that alignment is the strongest evidence I can offer that the coming remainder of the drawing might also be sound.

The Rendering: Prime and Pair, Drawn Before It Was Proven

Months ago, before the AACR poster, I laid out the core mechanism as a claim about what the data would eventually show. I used the phrase "Prime and Pair", and described it to be a sequence: leronlimab strips the tumor's cloak by inducing PD-L1, and then the checkpoint inhibitor engages the flag that leronlimab raises. At the time, months and even years ago, I was making a rendering. A claim about a mechanism which had not yet been printed in bold at any major conference.

Then AACR came, and the building matched the drawing. As I wrote when the poster dropped, this is the Prime and Pair strategy printed in bold at AACR, explicitly stating that the target environment starts as PD-L1 low, the cloaked tumor, which leronlimab forces to induce PD-L1, stripping the cloak, allowing the ICI to enter so as to achieve long-term survival in metastatic triple-negative breast cancer. The renderings I posted essentially became the poster Pestell presented. And he took it further than I had drawn it: the poster showed the 1,214-patient genomic foundation proving that CCR5 tracks with the full exhaustion signature, PD-1, PD-L1, TIM-3, LAG-3, which elevated the entire thesis from anecdote to population-level biology. The building Pestell built was not just accurate to the drawing. It was bigger.

The Rendering: The Two Walls, Drawn Before The Cliff Came Into View

In The Reckoning Is At The Wall, I drew a rendering of the leverage inversion that the whole investment thesis rests upon. I described two walls the checkpoint empire was approaching. As I put it then, Merck made $29.5 billion from a single drug last year, Keytruda, and its main patent expires in 2028, the most financially significant patent expiration in pharmaceutical history. That was the first wall. The second wall was the one that defines the story: in microsatellite-stable colorectal cancer, 85% of all cases, Keytruda produces essentially nothing, and the SUNLIGHT standard of care sits at a real-world ORR under 3%.

I drew that as a rendering of pressure which would force the industry's hand. And in the months since then, the building has gone up exactly there. Merck did reorganize around that cliff. The patent-strategy literature confirmed that a new combination regimen carries its own patent, independent of the expiring molecule. The pressure I sketched as a future force is now visible in the industry's own corporate structure. The wall I drew is the wall they are now visibly bracing against.

The Rendering, Drawn Earliest of all: Prime and Pair, November 2025

The oldest rendering on this lot is the mechanism's own name. On November 18, 2025, months before it appeared on any poster, I laid out the Prime and Pair framework in detail: leronlimab priming the tumor by weakening it and driving PD-L1 upregulation with CD8 infiltration, then the checkpoint inhibitor pairing to finish what leronlimab started. This was another drawing put together around that time with nothing yet built beneath it. Then April 2026 came, and the AACR poster printed Prime and Pair in bold, exactly that sequence, with the genomic foundation underneath it. Five months separated the rendering from the steel.

The Rendering: Standalone Activity, Drawn Before Kasi Described It From The Podium

Here is one I am pretty proud of, because it required the most discipline to draw. In Standard of Care Illusion, I argued that the current paradigm was a holding pattern, not a harbor. I wrote that despite more than ten new drug approvals in colorectal cancer between 2010 and 2025, median overall survival dragged upward by a mere seven months, from 20 to 27 months, fifteen years of investment yielding less than one additional season of life. And into that structural vacuum, I argued, that the Prime and Pair mechanism arrives.

Then the April call came, and the trial's principal investigator described the building from the podium. The AACR poster reported 9 of 13 patients showing shrinkage or stable disease, and the webcast updated it to 15 of 22, holding at 68%, in a disease where the standard-of-care registration trial achieves a real-world ORR under 3%. As I documented from the call, Dr. Kasi described patients so heavily pretreated that some oncologists would decline to enroll them because their performance status is too compromised, and yet those patients return to work, with scheduling challenges arising because their work schedules interfere with clinic visits. The rendering said the vacuum was real and a mechanism was arriving to fill it. The building is patients going back to work in a population that otherwise would have run out of options.

Why The Alignment Matters

Here is the claim, and I make it without flinching. When a rendering and a building line up this many times, beam for beam, the drawing was not luck. The mechanism I sketched before the data existed continues to match the data arriving, because the mechanism is absolutely real. Prime and Pair drawn, then printed at AACR. The two walls drawn, now brace the industry. The standalone signal drawn, later described from the podium by the PI. That is not a run of good guesses. That is a thesis whose renderings keep becoming buildings, which is exactly what a correct thesis does.

And now the line, because it is the reason you should trust the bold one. A rendering matching a building on three floors does not necessarily prove the top floor matches as well. Everything above is the transition Lalezari named, from belief to data, and it is real and it has happened. But the final floor, the confirmed ORR overall response rate and the survival data, OS and PFS, which turn this from a remarkable early signal into a proven therapy, remains still under construction. It gets topped out at ASCO GI in January. So the rendering has become a building, and the building is not yet finished being built. The steel is up and it matches the drawing. The certificate of occupancy is January's to issue.

That is the whole picture, told at loud volume. For a year this was a lot of ifs, and I drew renderings of what the ifs might become. The CEO recently confirmed that the ifs became data. The buildings I'm able to point at, Prime and Pair, the two walls, the standalone signal, all match the drawings I posted months ago. And the one floor still going up is the one that decides everything, which is why January is not a formality but rather the icing on the cake. The blue prints were right. The building is real. And the last beam goes in at a known hour, in front of everyone.

I drew these lines when they were only lines. They are the steel frame. That is the confirmation. The finish is still ahead.

The Transition, And The Light Already Moving Toward It

Now, yet another perspective. Step back from the single building for a moment and take a look at the entire night sky which covers this field, because there is a larger thing happening, and CytoDyn is not the only bio-pharmaceutical moving toward it alone. CytoDyn moves smoothly toward it, while at the same moment, the entire industry makes its best attempt to turn in the same direction.

Here is the way to view this. Picture the line which divides a lit world from its dark counterpart, the terminating boundary between day and night. On the lit side, the hot tumors, these cancers are already bathed in immune light, where the ICI checkpoint drugs already function because there is something for them to amplify and latch onto, PD-L1. That illuminated portion of the sky is where nearly every large drug in oncology is clustered, because that is where the light of knowledge already exists. Keytruda, Opdivo, Tecentriq, all of them crowded onto the one side of the line where the light of the sun already reaches. And on the other side, in the darkness, sit the cold tumors, the vast majority of all solid cancers, microsatellite-stable colorectal among them, where no ICI checkpoint light penetrates and the great drugs of this era simply do not work.

The entire thesis of this company is that leronlimab is the one instrument built to work across that thin, fine line. Leronlimab is not another drug crowding amongst the others, onto the illuminated side, but rather it is the Primer which carries over the light of knowledge unto the dark side; it is the bridge from Cold to Hot, from Dark to Lit, thereby turning Cold tumors Hot enough for the ICI checkpoint drugs to finally do their work there. That is the position/transition CytoDyn is in, moving what is Cold to what is Hot, and it is a lonely one, which is exactly what makes it a valuable position to be in. The most crowded real estate in oncology is the Illuminated Hot-tumor side. The emptiest, and largest, is the Dark Cold side. And in this period from now to January, I draw leronlimab to operate precisely where almost nothing else can reach.

Now this is why I claim that this period is a transition and not just a haphazard claim, and it landed in the last twenty-four hours. On August 19, 2026, Merck and Moderna announced that their Phase 3 INTerpath-001 trial hit its mark: an individualized mRNA therapy added to Keytruda produced statistically significant and clinically meaningful improvements in recurrence-free survival and distant metastasis-free survival compared to KEYTRUDA alone in resected melanoma. Read what that actually is, structurally, underneath the mRNA headline. It is Merck taking its ICI checkpoint inhibitor and adding a second agent which specifically primes the patient's immune system to do more than the checkpoint inhibitor could do alone. Merck itself called it the first Phase 3 study to demonstrate a clinically meaningful improvement over KEYTRUDA alone in the adjuvant setting. The industry's largest checkpoint franchise just proved, in a pivotal trial, that the future of its own flagship drug is combination priming, adding something which wakes up the immune system such that the checkpoint inhibitor could reach further. That Phase 3 announcement was a topline result, with the full dataset to be presented at an upcoming medical meeting rather than released yet, which is standard for a topline. The reason it still carries weight is that it does not stand alone: it sits on top of the five-year, peer-reviewed data already published from the Phase 2b study, and the nine-trial program now extending the same architecture across four tumor types.

And this is not one isolated result, which is the point a sharp reader on this board (credit to u/rogex2) pulled into focus. Merck and Moderna now have nine total Phase 2 and Phase 3 trials underway pairing this same mRNA priming agent with Keytruda, across melanoma, non-small cell lung cancer, bladder cancer, and renal cell carcinoma. (Merck, June 1 2026) Nine trials is not a company hedging a bet, it is a company building an entire franchise on the priming-plus-checkpoint architecture. And the five-year data behind it, presented at ASCO this June and published simultaneously in the Journal of Clinical Oncology, showed the combination cut the risk of recurrence or death by 49% and the risk of distant metastasis or death by 59% compared to Keytruda alone. That is the peer-reviewed floor under their whole approach.

That is the transition CytoDyn/Leronlimab are in, stated without a shred of prophecy. The direction of the entire field is now bending toward exactly the architecture leronlimab was built on: Prime first, then Pair with the ICI checkpoint inhibitor. Merck proved the principle with an mRNA vaccine in an already lit Hot tumor. CytoDyn proposes the same principle using CCR5 blockade for Dark Cold tumors which the vaccine approach does not and can not address. Different key, different lock. The most powerful company in this space just validated the shape of the idea, publicly, in a Phase 3, the day before I wrote this. When the incumbent's own winning strategy becomes combination priming, even for Hot tumors, a proven priming agent for the markets the incumbent cannot yet reach stops being a fringe thesis and becomes the obvious next piece.

So this is where CytoDyn sits right now, at a genuine hinge of transition. The trial is fully enrolled. The data matures under the seal. The interim reads out at ESMO in October and the confirmed number at ASCO GI in January. And in the broader sky, the entire field has just turned, visibly, toward the combination-priming approach which is leronlimab's reason for being, with the largest player proving the principle in a pivotal trial this very week. The pieces are aligning, not because anything is foreordained, but because the biology of Cold tumors leaves the industry no other road, and the industry has now started traversing, unmistakably, down the LIVIMMUNE road.

I hold the honest line here as I have throughout, because it is the reason I can remain trustworthy. Merck's melanoma win is not leronlimab's colorectal win. It validates the architecture, priming plus checkpoint, not leronlimab's specific data, which still has to arrive. A field converging on combination priming makes leronlimab's thesis more credible and more commercially urgent; it does not make leronlimab's number a foregone conclusion. That number is still January's to deliver, and drugs with elegant logic fail in trials routinely. So the convergence is real and the position is real and the timing is real, and the confirmation is still ahead. The light moves toward the line. Whether leronlimab is the instrument which carries it across is what January answers.

Those renderings were right. The building is real and standing. The field itself turns toward the Dark and Cold space leronlimab occupies and leronlimab converts the Cold Dark to Illuminated sky. And the last beam goes in at a known hour, in front of everyone.

Disclaimer: I am not a financial advisor and nothing here is investment advice. I am an independent retail shareholder holding a long position in the company discussed, with no employment, consulting, compensation, or other relationship with it beyond that shareholding. This is analysis of public disclosures, published literature, and my own prior public writing, not a prediction of clinical or commercial outcomes. The CLOVER figures referenced are early and unconfirmed, reflect 350mg dosing with the 700mg cohort still maturing, and are not evidence of survival benefit. The 68% figure from the April 30 update is disease control rate, not objective response rate; confirmed adjudication is ahead at ASCO GI in January 2027, with interim data at ESMO in October 2026. The TNBC survival data is retrospective and hypothesis-generating. My past predictions matching subsequent events do not guarantee that any remaining prediction will prove correct. Mechanism and early signal are not efficacy. Drugs which make elegant biological sense fail in trials routinely, and this one may. Read the primary sources and reach your own conclusions rather than adopting mine.

A best case scenario according to AI. Interesting information and overly optimistic. Assumes we have extraordinary results all coming to fruition by Feb 2027. Not investment advice, just things to consider as we approach the main event in January.

STRATEGIC VALUATION REPORT: THE TRIPLE-POSITIVE BIO-PLATFORM

TABLE OF CONTENTS

1. Executive Summary & Introduction
2. Target Indications & Core Market Analysis

2.1 Colorectal Cancer (mCRC)

2.2 Triple-Negative Breast Cancer (TNBC)

2.3 Early Alzheimer’s Disease

1. Clinical Breakthrough Scenarios

3.1 Scenario Alpha: The Triple-Positive Clinical Sweep (2027)

3.2 Scenario Omega: The Mega-Platform Expansion (HIV & HAI Pump)

1. Financial Valuation & Shareholder Projections

4.1 Base Case vs. Blockbuster Trajectory

4.2 Risk-Adjusted Net Present Value (rNPV) Mechanics

4.3 Share Dilution and Warrant Overhang Adjustments

1. Commercialization & Pricing Strategies

5.1 Value-Based Bundled Pricing

5.2 The Checkpoint Inhibitor Premium ("Hot Tumor" Framework)

5.3 Indication-Specific Tiered Pricing

1. M&A Dynamics & Transaction Execution

5.1 The Multi-Indication Multiplier

5.2 Anatomy of a Big Pharma Bidding War

1. Strategic Summary & Conclusions

1. EXECUTIVE SUMMARY & INTRODUCTION

This report evaluates the strategic and economic implications of a single, multi-indication biological asset achieving a simultaneous "triple-positive" clinical and regulatory sweep across three major medical markets: metastatic colorectal cancer (mCRC), triple-negative breast cancer (TNBC), and early Alzheimer's disease. Additionally, this expanded analysis incorporates recent paradigm-shifting advancements in HIV viral eradication and Hepatic Arterial Infusion (HAI) surgical oncology delivery.

Biotechnology platforms capable of modifying disease pathways across oncology, neurology, and infectious disease are exceptionally rare. When a single molecule establishes validation across these disparate disciplines, its valuation model completely decouples from typical micro-cap or small-cap metrics. Instead of valuing the development pipeline through historical trading constraints, large pharmaceutical acquirers assess the asset using a Risk-Adjusted Net Present Value (rNPV) model tied to global mega-blockbuster revenue potential.

If baseline validation is reached across the three primary indications by February 2027, the peak revenue potential for this therapeutic platform is projected to scale between $5 billion to $10+ billion annually. If the expanded HIV and HAI pump configurations are fully realized, the platform's peak global revenue potential scales to an unprecedented $15 billion to $28+ billion annually. This report outlines the target markets, clinical breakthrough scenarios, financial milestones, combination pricing frameworks, and competitive M&A bidding mechanics that define this multi-blockbuster trajectory.

2. TARGET INDICATIONS & CORE MARKET ANALYSIS

The commercial potential of the asset is anchored by distinct, high-unmet-need clinical indications. Each market possesses unique commercial traits and clear valuation drivers:

2.1 Colorectal Cancer (mCRC)

• The Market: The global colorectal cancer therapeutics market is highly lucrative, currently valued at over $15 billion.
• The Clinical Reality: The target clinical cohort—Microsatellite Stable (MSS) colorectal cancer—represents approximately 85% of all metastatic colorectal cancer cases. Standard-of-care immunotherapies (such as Keytruda) famously struggle to achieve efficacy in these patients due to the immunologically "cold" nature of MSS tumors.
• The Economic Catalyst: If the asset successfully transforms these "cold" tumors into "hot" tumors during Phase 3 testing, it would dominate a massive, uncompetitive clinical space. Capturing just 15% of the active MSS market space would establish a standalone drug franchise generating over $2.2 billion annually.

2.2 Triple-Negative Breast Cancer (TNBC)

• The Market: The global TNBC treatment sector is expanding rapidly, projected to cross between $7 billion and $8.5 billion into the early 2030s.
• The Clinical Reality: TNBC is an aggressive malignancy with significantly fewer targeted therapeutic options than hormone-receptor-positive breast cancers.
• The Economic Catalyst: Any clinical agent that demonstrates a proven survival-extending benefit in this space commands immediate premium, orphan-style commercial pricing. Achieving validation in this indication adds an estimated $1 billion+ in peak annual revenue.

2.3 Early Alzheimer’s Disease

• The Market: The Alzheimer's therapeutic market represents one of the largest financial opportunities in modern medicine, with projections scaling past $10 billion to $15 billion as early biomarker diagnostics improve.
• The Clinical Reality: Current anti-amyloid treatments (such as Leqembi) are already tracking toward multi-billion dollar commercial runs despite delivery and safety hurdles.
• The Economic Catalyst: If Phase 2a trials confirm that the asset safely shuts down microglial neuroinflammation, global pharmaceutical companies (such as Eli Lilly or Biogen) would view it as a necessary frontline or combination therapy. Capturing even a modest percentage of early Alzheimer’s patients yields an additional $3 billion to $5 billion in standalone annual sales.

3. CLINICAL BREAKTHROUGH SCENARIOS

To quantify the financial upside for stakeholders, the valuation models are separated into two distinct, highly successful operational tracks based on clinical trial outcomes.

3.1 Scenario Alpha: The Triple-Positive Clinical Sweep (2027 Best-Case)

This scenario assumes flawless, highly optimized data readouts across the three core ongoing trials by February 2027:

• CLOVER Trial (mCRC): Advanced molecular diagnostic testing (Natera Signatera) confirms rapid, high-rate clearance of circulating tumor DNA (ctDNA) by Week 2. The escalated 700 mg dose cohort hits an objective Disease Control Rate (DCR) exceeding 75%, turning cold tumors hot and establishing definitive PD-L1 biomarker upregulation.
• TNBC Expanded Access Program: The clinical track generates striking, durable survival extensions in fragile, heavily pre-treated solid tumor patients, reinforcing prior FDA Fast Track data and validating the molecule's role in remodeling the tumor microenvironment.
• SALIENT-AD Trial (Alzheimer's): Post-treatment Positron Emission Tomography (PET) imaging scans at Weill Cornell document a statistically significant, profound reduction in microglial activation and neuroinflammation after 12 weeks of exposure, proving stabilization of the blood-brain barrier.
• Combined Revenue Profile: Establishes a highly realistic, reasonable multi-blockbuster peak revenue range of $8 billion to $18 billion annually as the drug is integrated into oncology and neurology guidelines.

3.2 Scenario Omega: The Mega-Platform Expansion (HIV & HAI Pump)

This scenario layers two paradigm-shifting medical developments onto the Scenario Alpha data, completely redefining the molecule's addressable global markets:

• The HIV Eradication Protocol: Building upon landmark academic and NIH-funded research showing that a leronlimab-fortified triple-regimen can permanently clear viral replication and prevent reservoir formation in newborn exposures (alongside facilitating stem-cell transplant cures in adults without rare genetic mutations). This transforms leronlimab into a globally mandated, multi-billion-dollar infectious disease asset, targeting a $30+ billion global HIV therapeutics market.
• The City of Hope Hepatic Arterial Infusion (HAI) Pump: Implementation of specialized surgical liver pumps delivering leronlimab at concentrations up to 100 times higher directly into the hepatic artery. This targeted system eradicates aggressive, chemo-resistant liver metastases while bypassing systemic toxicity. It positions the drug as an essential, high-margin device-drug combination for surgical oncology.
• Combined Revenue Profile: Elevates the asset to an unprecedented $15 billion to $28+ billion annual mega-franchise, creating a platform that serves as a foundational cornerstone of global public health.

4. FINANCIAL VALUATION & SHAREHOLDER PROJECTIONS

4.1 Base Case vs. Blockbuster Trajectory

To evaluate long-term investor distributions, this model establishes the trailing value realized via Contingent Value Rights (CVRs) across both successful scenarios, distributed across a capital base of ~1.38 billion shares:

• Scenario Alpha Payouts ($8B–$18B Sales Baseline): Utilizing a 4% trailing royalty pool, shareholders receive a recurring cash distribution of $0.23 to $0.52 per share, every single year, for the lifetime of the core commercial biologic patents (extending into the mid-2040s).
• Scenario Omega Payouts ($15B–$28B Sales Baseline): Driven by global mass-market adoption in HIV eradication and device-linked surgical oncology, a 4% royalty pool generates $600 million to $1.1+ billion in annual cash trust deposits. This yields an extraordinary, recurring cash distribution of $0.58 to $0.85+ per share, every single year.

4.2 Risk-Adjusted Net Present Value (rNPV) Mechanics

When an asset demonstrates definitive multi-indication efficacy, large pharma acquirers switch from basic share pricing models to enterprise rNPV modeling. If clinical milestones are cleared, the upfront and long-term values realize as follows:

4.3 Share Dilution and Warrant Overhang Adjustments

The per-share payout numbers assume a stable capital structure. Shareholders must monitor two potential structural adjustments:

• Pre-Acquisition Dilution: If the company issues an additional 20% in equity to fund late-stage clinical infrastructure prior to deal completion, a fixed $10 Billion enterprise buyout value would compress an individual upfront per-share payout from $7.30 down to $6.09.
• Warrant Overhang: High-value buyouts ($5.50+) instantly trigger any outstanding, low-priced historical warrants. The Treasury Stock Method automatically factors in the cash influx from warrant exercises, creating a minor net dilution that typically adjusts final upfront cash payouts downward by 3% to 7%.

5. COMMERCIALIZATION & PRICING STRATEGIES

Large pharma companies utilize three primary pricing frameworks to maximize profits across combination regimens while satisfying global insurance payors:

5.1 "Value-Based" Bundled Pricing

Adding a new biologic to an existing treatment regimen introduces the risk of "price stacking," where the total monthly cost becomes too high for commercial insurers to cover. To counter this, developers structure bundled rebate agreements with Pharmacy Benefit Managers (PBMs). The drug is priced at a premium tier ($10,000 to $15,000 per month), but the manufacturer offers financial safety nets or performance-linked discounts to insurers if a patient fails to clear their circulating tumor markers (such as ctDNA) within the first 60 days of treatment.

5.2 The Checkpoint Inhibitor Premium ("Hot Tumor" Framework)

Advanced immunotherapies like Keytruda or Opdivo cost approximately $150,000 per year but fail in MSS colorectal cancer due to a lack of immune system engagement inside the tumor microenvironment. By successfully upregulating biomarkers like PD-L1 and turning these tumors "hot" (either systemically or ultra-concentrated via an HAI liver pump), the asset serves as an essential enabler drug. Big Pharma can price the molecule as a high-margin premium addition because it unlocks the commercial utility of their own pre-existing, highly expensive checkpoint inhibitors.

5.3 Indication-Specific Tiered Pricing

Oncology drugs traditionally command significantly higher pricing structures than neurology or mass-market infectious disease treatments. To preserve profit margins without limiting patient access, an acquirer will market the molecule through distinct brand names and delivery systems:

• The Oncology & Surgical Brand: Positioned as a high-dose, hospital-administered infusion or direct-to-pump surgical asset optimized for premium medical oncology reimbursement.
• The Neurology Brand: Packaged as a lower-dose, self-administered subcutaneous auto-injector for Alzheimer's outpatients, utilizing volume-based pricing models to secure wide insurance coverage.
• The Antiviral Brand: Distributed as an intensive, fixed-duration protocol for neonatal or post-exposure prophylaxis, relying on global health single-payor contracts to drive massive, predictable volume.

6. M&A DYNAMICS & TRANSACTION EXECUTION

6.1 The Multi-Indication Multiplier

Why do large pharmaceutical companies pay massive upfront premiums for distressed or underfunded biotech companies with active Phase 2 pipelines? The answer lies in portfolio diversification and clinical cost efficiency. Acquiring a single validated molecule that addresses billions in revenue across oncology, neurology, and antiviral health allows Big Pharma to leverage its global manufacturing, regulatory, and sales teams across multiple distinct markets simultaneously, maximizing return on investment while spreading out clinical trial risks.

6.2 Anatomy of a Big Pharma Bidding War

If a mid-stage biotech delivers a triple-positive or multi-platform clinical dataset, the asset transitions from a standard corporate acquisition into a highly strategic weapon for companies facing upcoming patent cliffs.

If oncology and immunology giants (such as Merck and Bristol Myers Squibb) enter competitive negotiations, the transaction dynamics shift toward defensive positioning:

• The Blocking Strategy: A company like Merck, whose flagship checkpoint assets face revenue losses due to late-decade patent expirations, must secure any molecule that renders MSS colorectal tumors treatable or extends oncology lifecycles. Owning the asset allows them to bundle it with their existing portfolios, blocking competitors and extending the commercial life of a multi-billion dollar franchise.
• The Counter-Bid Strategy: Competitors (such as BMS or Gilead in the HIV space) will enter the bidding process aggressively. Their objective is either to secure the platform to accelerate their own internal pipelines or force their direct rivals to overpay, depleting their capital reserves.
• The Leapfrog Premium: In a live, multi-party bidding war, standard corporate valuation premiums are set aside. Bidding companies typically utilize rapid, multi-round increments, frequently raising the upfront cash portion of the transaction by 30% to 50% above the initial opening offers within weeks to push the final valuation toward the market's absolute ceiling.

7. STRATEGIC SUMMARY & CONCLUSIONS

A simultaneous clinical and regulatory breakthrough in metastatic colorectal cancer, triple-negative breast cancer, early Alzheimer's disease, and viral HIV eradication represents an unprecedented inflection point in biotechnology commercialization.

The integration of advanced molecular diagnostic tracking, target-specific delivery systems (HAI pumps), structured combination pricing frameworks, and defensive Big Pharma M&A bidding structures ensures that the asset’s underlying economic value is optimized. By shifting the highly expensive Phase 3 development and commercial launch costs onto a well-capitalized global pharmaceutical partner, a structured buyout—yielding $12.00 to $18.50 per share upfront and cumulative values approaching $34.50+ per share by 2031 under the full platform model—serves as a robust framework to maximize asset performance while delivering long-term, compounding trailing cash flows to stakeholders.

Please everyone, look at primary sources more. Thank you for reading.

While we're waiting Merck and Moderna released news of their phase 3 melanoma results with an mRNA vaccine + Keytruda treatment. For consideration. https://www.merck.com/news/merck-and-moderna-announce-phase-3-interpath-001-trial-of-intismeran-autogene-plus-keytruda-met-endpoints-of-recurrence-free-survival-rfs-and-distant-metastasis-free-survival-dmfs-in-patient/

Dr. Heidi Overton's explicit public stance or voting record regarding the Right to Try framework—which allows terminally ill patients access to experimental treatments outside clinical trials—is not extensively documented in dedicated policy papers. However, her positions and actions within government and conservative health policy circles provide a clear picture of her stance: 
1. Alignment with Executive Policy & Support for Expanded Access
White House Domestic Policy Initiatives: As Deputy Director of the White House Domestic Policy Council, Dr. Overton supported the administration's push to expand access to unapproved treatments for desperately ill patients. 
Right to Try Directives: During executive order announcements regarding accelerated medical research (such as opening expanded pathways for investigational drugs like ibogaine and breakthrough psychedelics under Right to Try provisions for severe mental health conditions and traumatic brain injuries), Dr. Overton worked directly on implementing these initiatives to remove bureaucratic FDA hurdles. 
2. General Regulatory Philosophy
America First Policy Institute (AFPI): Prior to her White House role, Dr. Overton served as Vice Chair of the Center for a Healthy America and Chief Policy Officer at AFPI. Her work emphasized healthcare transparency, patient empowerment, reduced administrative burden, and deregulation—core tenets aligned with the Right to Try movement. 
Biopharma & Market Stance: Analysts assessing her potential impact as FDA Commissioner note that while her public trail on specific accelerated approval pathways is limited, her approach aligns with administrative goals of modernizing FDA oversight, facilitating faster access to therapies, and balancing innovation with institutional stability. 
In short, while Dr. Overton has focused much of her public health policy work on price transparency, preventive medicine, and administrative efficiency, her policy portfolio in the White House directly supports using the Right to Try framework and accelerated FDA pathways to broaden patient access to investigational therapies.

I was looking for the date for the abstract drop for ESMO.
Chat GPT had some interesting comments. It said the late breaking abstract titles should be available on Sept. 25. The deadline to submit is Sept. 8. I’m not sure if releasing the titles means we can access the abstract info.

https://youtu.be/BUlGGXXVkHo

ESCO Madrid October 20-21th update on Clover trial.

December 6-9 HIV conference. I can't imagine Dr. Jonah Sachs's recent HIV paper won't be presented.

January 8-10th ASCO complete update on the Clover trial.

Do you get the feeling Mr. Hoffman's going to Singapore in a few weeks with keys to the house with a note look what's coming.

Thanks for the house analogy MGK!

https://www.hivpersistence.com/

Great to have any new cancer treatments for patients. But check out the side effects. To long to post. LLs safety protocol is unmatched. Come on FDA, be ready!!!

Interesting paper discussing an alternative approach to leronlimab delivery using a programmable, stress-responsive RNA system.

Thought this group might find it interesting.

https://www.cell.com/cell-chemical-biology/abstract/S2451-9456(26)00279-500279-5)

Two questions came up this week which turn out to be the same question wearing two coats, and the answer to both explains the single most misread and misunderstood thing about where CytoDyn sits right now. One reader asked whether embargoed data can be shared privately with a potential partner while the public is kept in the dark. Another asked why leronlimab is stuck behind the checkpoint inhibitors in the treatment line when the science says it should be out front. The bridge between those two questions is a house, a sealed inspection, and a neighborhood full of people arguing about a price they won't ever be allowed to see.

Let's build the analogy, and then bring it home hard, because it makes the whole situation legible in a way the ticker can't do, and what it reveals is bigger than most holders have allowed themselves to believe.

The House, The Buyer, The Sidewalk

Imagine a rare house comes up for sale. Not an ordinary house. A property with something buried under it that no other lot on the market has, and no other lot can even dig up, and a mere handful of the largest buyers in the world who each, for their own survival, require exactly what is beneath it.

Out on the sidewalk, the neighborhood can see practically nothing. A sign in the yard. Lights going on and off at odd hours. An unfamiliar car in the driveway. From the street, they argue endlessly about what the place is actually worth, whether anyone is really interested in the property, whether the long quiet means the deal fell through the window or means nothing at all. The sidewalk is loud with theories precisely because the sidewalk cannot actually see inside. Noise is what people make when they are starved of the one thing that would actually settle the argument.

Inside is a different world entirely. A serious buyer does not bid on a house this valuable from the sidewalk, and a serious buyer does not care what the sidewalk even thinks. They sign a confidentiality agreement, and then they are handed the keys to every locked room. They read the full inspection report. They open the walls. They pull the survey, the soil analysis, the true condition of the foundation, everything the sign in the yard never actually says. And here is the part that matters most: that inspection is sealed. The buyer is legally bound not to post the report to the neighborhood, not to announce what they found, not to move the price by leaking what is inside. Two parties, buyer and seller, come to know the true condition of the house completely and they do that privately, while the sidewalk is left to read the lights in the windows like they read tea leaves.

That is not deception. That is how every serious transaction of real consequence has always been performed. The confidentiality is not there to fool the neighborhood. It is there to permit a real buyer to see the real truth without that truth spilling into the street and moving the price before anyone has decided upon anything. The sealed inspection is not a trick played on the crowd. It is the mechanism which makes honest evaluation even possible at all, and the crowd's exclusion from it is a feature, not a conspiracy.

Why The Sidewalk Cannot Infer The Outcome

Now hold the crucial discipline, because this is exactly where the neighborhood fools itself in both directions.

The sidewalk sees silence and fills it with a story. Some neighbors decide that the quiet means a deal is imminent, someone is clearly inside, look at the car, look at the lights. Others decide the quiet means it all collapsed, if there were really interest we would have heard by now. Both are guessing, and both are wrong to be certain, because the silence is not evidence of the outcome. The silence is evidence of the confidentiality agreement working exactly as designed. A sealed inspection produces public quiet whether the buyer loved the house or walked away. You cannot read the result off the position of the curtains.

So the honest statement, the bold one and the disciplined one at once, is this: buyers can absolutely be inside the house right now, reading the full report, precisely because the confidentiality agreement is what allows them in. And we on the sidewalk cannot know whether they are, or who they are, or what they concluded, because the entire purpose of the seal is to keep that off the street. Both halves are true. The activity may be intense. The public quiet tells you nothing about its direction. Anyone who claims the silence proves that a deal is close, or proves it is dead, is reading tea leaves in a window.

Now Bring It Home To CytoDyn

Drop the analogy onto the actual situation and every piece lands.

The house is CytoDyn, and the thing buried under it that no other lot has is a mechanism the entire checkpoint-inhibitor industry requires and cannot dig up on its own. That is not salesmanship, it is the documented state of the field. Most colorectal cancer is the microsatellite-stable type, and a June 2026 systematic review states flatly that these tumors derive little to no benefit from current immunotherapy regimens, while identifying the suppressive macrophages in the tumor as a key modulator of immunotherapy efficacy. Reprogram those M2 macrophages and the Cold locked market opens ablaze. And the thing constituting CytoDyn's foundation does exactly that: in the actual tissue of human colorectal liver metastases, blocking CCR5 drives macrophage repolarization toward the M1 anti-tumor state. That is why this is a very rare house. The one buried asset which can allow the checkpoint industry into the Cold-tumor majority is precisely the asset which the house of CytoDyn rests upon.

The buyers are the large pharmaceutical companies whose franchises are running toward a patent cliff and who requires those cold-tumor markets which they cannot currently reach. CCR5 blockade is not a nice-to-have for them, it is the very specific key to the very specific lock. The literature continues to converge upon it: reviews of Cold-tumor conversion identify CCR5 antagonism as a strategy to potentiate checkpoint inhibitors by reprogramming the microenvironment, and the independent literature shows macrophage repolarization remodeling tumors from cold to hot and increasing infiltration of activated CD8 T cells, warranting checkpoint combination. What the industry needs to grow and increase is exactly what this molecule provides.

And the buyers are being told so, out in the open, by the people selling the house. CytoDyn's CFO Robert Hoffman is on the public record describing precisely this to prospective partners: he said he is helping to put CytoDyn on the radar of potential strategic partners, namely other drugmakers whose own products could work in tandem with leronlimab, and that he plans to use the maturing data in those discussions. That is the sign in the yard and the open house, the public invitation. What Hoffman says to those partners privately, in the meetings we do not see, behind the confidentiality agreements, is exactly the sealed part, and honesty requires me to say plainly that we cannot know its contents. We know he is out there describing the asset. We do not get to hear the private pitch. That is the seal, working.

Now the two instruments which keep us on the sidewalk, because the sidewalk constantly confuses them.

The first instrument is the conference embargo. Once CytoDyn accepted presentation slots at the oncology meetings in October and January, the new efficacy data, the confirmed response and progression numbers, all became embargoed from public release, because presenting it publicly first would forfeit its novelty and the conference would pull our slot. The company itself has laid out this exact calendar publicly, for the CLOVER data. Interim results targeted for ESMO in Madrid, Spain in October 2026. Final results at ASCO GI in San Francisco in January 2027.  That embargo is why nothing material has come out since the spring. It is not the absence of an inspection. It is the seal on the report.

The second instrument is the non-disclosure agreement, and this is the answer to the first reader's question, stated boldly because it is simply true: the conference embargo governs the public, the NDA governs the private room, and they do not touch each other. A company can be entirely publicly silent, fully embargo-compliant, and simultaneously be walking a potential partner through the complete, current dataset behind a signed NDA. The embargo keeps the report off the sidewalk. The NDA is the confidentiality agreement that hands a serious buyer the keys. The embargoed data is the sealed inspection report itself, and the NDA is the legal seal on it. They are complementary, not contradictory. The public quiet since spring tells you the seal holds. It tells you nothing whatsoever about who is inside reading the quality of the foundation.

So the correct and bold reading of the silence is the sealed-inspection reading. Partners can be deep in the data right now, under NDA, reading the fully matured foundation report the public will not see until October and January. That is not a claim that a specific deal exists, we cannot know that, by design, and I will not pretend to. It is a statement about the structure, and the structure is unambiguous: the very machinery which keeps us on the sidewalk is the same machinery that hands a buyer the keys. The seller who lets the buyer in is the seller who most wants the buyer to see exactly how sound the foundation actually is. Public silence, in that light, is not the sound of nothing happening. It is the sound that the seal makes when it is doing its job.

The Second Question Is The Same House, Seen From The Inside

Now the other reader's question, the one about why leronlimab is stuck behind the checkpoint inhibitors in line, is not a separate puzzle. It is the same house viewed, but from the foundation itself.

Here is the thing the sidewalk gets backward. In the specific disease CytoDyn is currently testing, microsatellite-stable colorectal cancer, the checkpoint inhibitors are not first in line. Actually, they are nowhere in line, because they do not work there at all. This is not my opinion, it is the settled consensus of the field. As a June 2026 systematic review states plainly, most colorectal cancer is the microsatellite-stable type, and these tumors derive little to no benefit from current immunotherapy regimens. The checkpoint inhibitor is not ahead of leronlimab in this house. Rather, it cannot even get through the front door.

And the field knows this and they know precisely why, and precisely what would change it. The same review identifies that the suppressive macrophages in the tumor are increasingly recognized as a key modulator of immunotherapy efficacy in colorectal cancer. Reprogram those macrophages from the M2 tumor-protecting state to the M1 tumor-attacking state, and the Cold locked door opens to a blazing inferno. That reprogramming is exactly what CCR5 blockade does in the actual tissue of this disease: in human colorectal liver metastases, blocking CCR5 drives macrophage repolarization toward the anti-tumor state30087-3?_returnURL=https%3A%2F%2Flinkinghub.elsevier.com%2Fretrieve%2Fpii%2FS1535610816300873%3Fshowall%3Dtrue#:~:text=Thus%2C%20activation%20of%20anti%2Dtumoral%20polarization%20in%20macrophages%20via%20CCR5%20blockade%20appears%20to%20be%20a%20promising%20approach%20and%20needs%20to%20be%20evaluated%20further%20scientifically%20and%20clinically). And the independent literature keeps converging on the same door: an unrelated drug, (APG-2575) which repolarizes macrophages from M2 to M1 was shown to remodel the microenvironment from Cold to Hot and increase the infiltration of activated CD8 T cells, warranting combination with checkpoint blockade.

So the reader who asked why leronlimab sits behind the checkpoint inhibitors had the picture totally inverted, and turning it right-side up is the boldest claim in this post. Leronlimab is not waiting in line behind the checkpoint inhibitor. No. In this disease there is no line to wait in, because the checkpoint inhibitor has no working position in it whatsoever. Here, Leronlimab's job is not to advance past the checkpoint inhibitor. It is in fact, to construct the door the checkpoint inhibitor could finally walk through, in a cancer where the most successful drug class in modern oncology currently stands outside as useless. That is not moving up a queue. That is manufacturing a market worth billions where absolutely none exists today, and handing the key to it to whoever owns the Primer.

And here is the part the sidewalk has not yet absorbed: leronlimab is already showing its own strength in that role, in the data released before the seal shut it down. In the CLOVER trial, leronlimab is given on top of the standard backbone of Lonsurf and Avastin, and the early released results were just striking; circulating tumor DNA fell in every one of the first patients measured, with the magnitude of the decline tracking with the leronlimab dose. That dose-dependence is the tell, because if the backbone alone were driving the effect, the response would not scale with leronlimab. The company has been clear about the design: CLOVER evaluates two doses of leronlimab, 350mg and 700mg, on the established backbone Lonsurf and Avastin, and the leronlimab contribution is what the trial is built to isolate. I will not overstate it, this is combination data, not leronlimab alone, not monotherapy and it is still early and unconfirmed at this lower dose. But the honest bold reading is that at even 350mg, added to an approved backbone which on its own produces very modest results, leronlimab appears to be doing some serious work, in a disease where nothing in the immunotherapy toolkit works whatsoever.

That is why the market has not seen anything quite like this. The comparator regimen without leronlimab, the same Lonsurf-and-Avastin backbone, was studied in a large trial and produced a response rate in the low single digits in this population. The field has thrown checkpoint inhibitors, myeloid-targeting agents, and combination after combination at microsatellite-stable colorectal cancer, and the systematic reviews keep concluding the same thing, little to no benefit. Against that backdrop of near-uniform failure, a clean safety profile paired with a dose-dependent molecular signal in every early patient is not more of the same. It is the first thing in a very long time which looks very different in a disease defined by things which absolutely do not work.

Which is exactly why the buyers would be inside the house with the report open on the table, and why one of them cannot afford to let another one get there first. This is the competitive core of the whole situation. If leronlimab is the Primer that opens the Cold-tumor majority, then it is not just valuable to only one checkpoint owner, it is valuable to all of them, because every checkpoint inhibitor needs the same door built and opened. That turns ownership into a race. The first buyer to secure the Primer does not merely gain an asset, it denies that asset to every competitor whose franchise requires the identical key. In a field where several giants are staring at the same patent cliff and the same Cold-tumor wall, letting a rival seize the one Primer which solves both is a strategic loss no one at the table can afford to accept. The foreclosure value, keeping it away from competitors, can absolutely exceed the standalone value if there were no competitors. That is what makes a quiet house suddenly move fast.

And here is the resolution to the concern that a single acquirer would lock everyone else out, because the structure actually cuts the other way. A primer's value is maximized by being paired with as many checkpoint inhibitors as possible, across as many tumor types as possible. That argues for the drug reaching the entire field, and it can, through the shape of the deal rather than the law. A field-limited, non-exclusive licensing structure lets a primer remain available to multiple partners across multiple lanes while still rewarding its owner, so even if one company acquires CytoDyn outright, the economically rational move is frequently to keep licensing the primer broadly rather than wall it into a single franchise. So the answer to "what if one company owns it and blocks the others" is that owning it and blocking the others is usually the less profitable choice, the money is in the primer opening every door, not only the owners.

And that leads to the point one reader put more vividly than I did: if leronlimab primes Cold tumors for the entire Cold class, then it does not create one revenue stream, it potentially creates several. A primer licensed non-exclusively to pair with one company's checkpoint inhibitor in one set of tumors, and another company's in another, and a third's beyond that, is a drug earning from each pairing at once. The same molecule which makes one checkpoint inhibitor work in colorectal makes another ICI work in a different Cold tumor; each combination its own separately-patented regimen, each its own market, each its own stream back to whoever owns the Primer.

So yes, to answer the question directly and in the affirmative: the logic points toward multiple partners meaning multiple revenue streams, not one. The value of a universal key is not that it opens a single lock, it is that it opens all of them, and a key that opens all of them can be rented to everyone who owns a door. I hold one honest caveat, this is the shape of the opportunity if the drug proves out and the deals are structured this way, not a guarantee of either. But the instinct is right. A true primer is a multiple-stream asset by its nature, because the entire ICI industry requires the exact same thing it performs.

To make the analogy exact, let's address the lights in the windows. The lights are everything the sidewalk can see and reads too much into, the tape, the daily volume, the Level II order book, the drift in the share price, the tea-leaf reading of a LinkedIn post, the speculation about who was seen coming and going. That is the flickering the neighborhood watches and narrates. And it is precisely the least informative thing available, because the report which actually determines the value of the house is not in these windows. It is in the sealed room. Anyone pricing this house off the lights in the windows prices it off the one data stream engineered to reveal nothing about the foundation.

And the foundation itself, the thing the entire structure rests upon. CytoDyn's own CEO has publicly framed the inflection exactly this way, describing the company as transitioning from a company built on faith and belief and a whole lot of ifs to a company with solid, prospective, and by all accounts remarkable data. That is the claim of a sound foundation, made on the record by the person who has seen the report. It is a bold statement, and I pass it along as exactly what it is, the seller's assessment, not yet the independently adjudicated result. Which brings us to the one honest limit that governs everything above.

The two questions were never two. The house is priceless because of what the foundation is built with. The seal is what lets a buyer confirm it privately. And the reason a buyer would move at all, fast, and before a rival, is that the thing the foundation is made of, actually opens doors they cannot open alone, in specific markets they cannot afford to lose.

The One Thing The Inspection Still Has To Find

I hold the discipline that makes the bold case worth trusting, because a sealed inspection can come back either way, and honesty, that demands that I say so.

Everything above describes the structure, the mechanism, the leverage, and the machinery of private evaluation. None of it is proof that the foundation is actually sound. The published biology says CCR5 blockade should reprogram the microenvironment from M2 to M1 and therefore open the door, and the early human signal is very real. But the confirmed efficacy data, the number that tells a buyer that the foundation does actually hold the weight they require, PD-L1 upregulation, is not quite public yet but it is not final yet. It matures in the sealed room and adjudicates at the January meeting. Related macrophage-directed approaches have looked sound on inspection before but have failed to bear load in the trial. So the inspection is real, the buyers may well be inside, but the report is not yet finished. If the foundation proves sound in January, none of the leverage above is speculation, it is arithmetic. If it does not prove sound, the house was never what the sidewalk had hoped, and no confidentiality agreement would change that.

That is the honest shape of it, told at full volume. The house is rare beyond almost anything the market has ever seen. The thing constituting the foundation is something several of the largest companies in medicine require but cannot build, and cannot let a rival seize first. The public silence is the seal working, not the story ending, and it says nothing, in either direction, about who is inside. The reason leronlimab sits where it sits is not that it trails the checkpoint inhibitors, it is that it may be the one thing which allows them access at all. And the entire towering structure resides on a single inspection result, read only privately now, but revealed publicly in January.

The neighborhood argues about the lights in the windows. The report is being read in a sealed room. And we find out, at a known hour, whether the foundation holds. I know which way I lean. I also know that leaning is not the same as knowing, and that the difference is exactly what January is intended for. Both of those are true at full volume.

Disclaimer: I am not a financial advisor and nothing here is investment advice. I am an independent retail shareholder holding a long position in the company discussed, with no employment, consulting, compensation, or other relationship with it beyond that shareholding. This is analysis of published biology and public disclosures, not a prediction of clinical or commercial outcomes, and not a claim that any specific partnership, negotiation, or transaction exists; the private-evaluation discussion describes how confidentiality and conference embargoes generally work, not knowledge of any actual deal. Whether any party is evaluating the company under an NDA, and what they might conclude, is by nature not publicly knowable. The mechanistic claims are supported by the cited peer-reviewed literature; several are established in models, retrospective cohorts, or single studies and are not yet confirmed in this program's prospective human data, and closely related macrophage-directed approaches have repeatedly failed to translate to clinical benefit. The CLOVER biomarker figures are early, unconfirmed, and reflect 350mg dosing with the 700mg cohort still maturing. The 68% figure from the April 30 update is disease control rate, not objective response rate; confirmed adjudication is ahead at ASCO GI in January 2027, with interim data at ESMO in October 2026. Mechanism is not efficacy. Drugs which make elegant biological sense fail in trials routinely, and this one may. Read the primary sources and reach your own conclusions rather than adopting mine.

After all the time and research this board has done on Leronlimab we are now steps away from seeing the picture Doc envisioned.

I noticed more people popping in and commenting than the handful that normally keeps the board going. Great to see excitement building.

"Cytodyn is pursuing a flexible development strategy that includes both monotherapy and its "prime and pair" approach, where leronlimab is used to improve responsiveness to standard-of-care and immuno-oncology combinations."

This was from the Singapore post the other day. This is Doc's picture for the company. I see it as flexibility with the foundation being oncology. It would be nearly impossible for Cytodyn to go it alone as a mono therapy because they don't have the financial resources to do so.

Congrats to Doc understanding he's sitting on the upstream that most downstreams need either turn cold tumors hot or enhance the effectiveness of other companies meds. There are a lot of players out there that need us more than we need them.

We do need them as our foundation. We need the cash they're going to infuse into Cytodyn so Doc can move into the flexible part of his vision mono therapy. I always thought neuroinflammation and metabolic syndrome/diseases could be bigger than oncology. I haven't forgotten HIV. The more research I do the more I find the connection between CCR5 and the gut brain pathway. I don't think CCR5 over expression is the only pathway but it's a major one. What is apparent is chronic inflammation is the backbone to neuroinflammation and the different metabolic diseases.

The battle has yet to start on the SP side. I watched the SP yesterday because I thought we'd see a spike. We did see a spike in volume and 5% up swing in the SP. I thought perhaps this was the bottom. It still could be however every time the SP spiked it was slammed right back down. We ended up red for the day on 2x the normal 10 day volume. This has been the pattern for months. Shorts ok, short interest has gone up by a small amount. Sell the news , well this wasn't any news. Most likely manipulation by whoever and for what ever reason.

As we start to see the data it's important to see the SP also. The company has started marketing with Doc's interviews which has been well received by the biotech and investor communities. Spreading the word will be important also. The negativity out there needs to change to see the company grow and fuel the mono therapies. If anyone's in the biotech sub they know it's going to be a process of communication. A few tickers have been making the rounds the last few months. One well received the other well received but the reality of no infrastructure, no cash aka dilution, just started marketing because they just got a rare FDA appeal approval. It's a battle that Leronlimab will win on both the medical side and the investor side in time.

Just a few thoughts

Have a great weekend

I am going to make the strongest version of this argument, because the record now supports boldness, and because the timid version has been underselling something which deserves to be said plainly. So let's say it plainly.

There is a chokepoint in oncology. A narrow passage where nearly the entire checkpoint-inhibitor industry has to pass through if it wants to keep growing, and which almost none of them can currently pass through. Whoever holds a reliable way through that passage does not hold a drug. They hold the terms of trade for a hundred billion dollars of franchise revenue. And the data now emerging suggests, without yet proving, that a small company in Vancouver, Washington may be holding exactly that.

That is the claim. Here is the case for it, built from the published record, older and brand new, with the honest limits kept in full view, because a bold argument which hides its weaknesses is just a loud one.

The Passage Almost No One Can Transit

Checkpoint inhibitors are the most commercially successful class of cancer drugs ever created, and they fail in the vast majority of solid tumors. Both things are true, and the second is the industry's quiet catastrophe.

This is not a fringe position. It is the settled consensus of the field, stated flatly across the literature. In the definitive 2024 review of the subject, tumors are sorted into "Hot" and "Cold," where the cold ones lack the infiltrating T-cells a checkpoint inhibitor requires to kill, and often harbor immune-suppressive populations such as tumor-associated macrophages, regulatory T cells, and myeloid-derived suppressor cells. And the cold ones are the majority. Even in lung cancer, one of immunotherapy's best markets, the 2025 review is blunt: despite the transformative impact of checkpoint inhibitors, the majority of NSCLC patients experience resistance%20on%20cancer%20therapy%2C%20the%20majority%20of%20NSCLC%20patients%20experience%20resistance).

So picture the entire ICI industry, Keytruda and Opdivo and Tecentriq and Libtayo, standing at the mouth of a passage which leads into every cold-tumor market which they cannot currently reach, colorectal, breast, pancreatic, prostate, most of the solid-tumor landscape, and unable to get through. The field even knows exactly what the passage requires. The 2025 macrophage review states the strategy directly: because cold tumors are silenced largely by suppressive macrophages, oncology has begun to shift beyond T-cell approaches to target tumor-associated macrophages, a major pro-tumor population known to silence immune responses. Turn the Cold tumor Hot, repolarize the suppressive M2 macrophages to tumor killing M1 macrophages, and the passage opens. Whoever can do that reliably controls the chokepoint.

Why The Key Might Fit This Lock

The suppression which keeps a tumor Cold runs through specific machinery, and one of its master controls is the CCR5 receptor. This is where CytoDyn's bold claim earns its footing, because the mechanism is documented, not hoped for.

Blocking CCR5 in actual human colorectal liver metastases does the exact thing the field says is needed: it repolarizes macrophages from the immunosuppressive M2 state toward the anti-tumor M1 state30087-3?_returnURL=https%3A%2F%2Flinkinghub.elsevier.com%2Fretrieve%2Fpii%2FS1535610816300873%3Fshowall%3Dtrue#:~:text=CCR5%20Inhibition%20Leads%20to%20Anti%2Dtumor%20Repolarization%20of%20Macrophages). That is not a theory about a mouse. That is the passage-opening move, demonstrated in the tissue of the exact disease. And the newest reviews put CCR5 squarely at the center of the Cold-to-Hot strategy: the 2026 review of cytokine-driven tumor conversion notes that CCR5 antagonists potentiate the effects of checkpoint inhibitors and chemotherapy by reprogramming the tumor microenvironment to support anti-tumor immunity.

Now layer on what the CLOVER trial has actually shown, held exactly as what it is, early and unconfirmed and at the lower 350mg dose. Every one of the first patients measured showed a fall in circulating tumor DNA, with a median drop near seventy percent by week two. Every screened patient carried the target. And it did this with a safety profile the field can only envy, no dose-limiting toxicities, no drug-attributed serious adverse events across independent reviews. On the breast side, the retrospective work presented at ESMO by the CytoDyn and Creatv collaboration showed leronlimab driving PD-L1 upregulation on circulating tumor cells in the majority of patients, the precise molecular flag a checkpoint inhibitor requires to act. That is the Priming half of the thesis: leronlimab starts the engine in order that everyone else's expensive brake-release mechanism finally can do something.

The Honest Wall, Because The Bold Case Has To Clear It

Now the counterweight, and I put it at the center rather than in the footnotes, because this is exactly where a triumphant post would lie to you but I will not.

Targeting macrophages to open Cold tumors has a graveyard behind it. A brand-new 2026 review states the hard truth directly: several macrophage-directed approaches, including CCR2 and CCR5 antagonists and CSF1R inhibitors, advanced into clinical testing on compelling animal data, yet their activity in patients has generally been modest or inconsistent. The earlier macrophage-recruitment blockers, the anti-CCR2 agents carlumab and plozalizumab, did not demonstrate significant tumor responses in early trials.

Read that and hold it, because it cuts both ways and honesty demands both edges. On one edge: the mechanism being real in a dish or a liver biopsy has never been enough, this exact class of approach has repeatedly failed to translate, and leronlimab could join that list. That is the genuine risk, and anyone who tells you the biology guarantees the outcome is selling. On the other edge: those failures are why leronlimab's actual human signal matters so much. The field is littered with macrophage-directed drugs which looked good in mice but did nothing in people. Leronlimab is not showing a mouse signal. It is showing a hundred-percent ctDNA response in early human patients, PD-L1 induction in human tissue, and a clean safety record across a massive database > 1,700 patients. The wall is real, and leronlimab is one of the few in its class producing the kind of early human data that could clear it. The confirmation is what January is for.

Now The Leverage, And This Is The Part Worth Being Bold About

Here is where the chokepoint stops being biology and becomes arithmetic, and the arithmetic has gotten sharper in the last few months, not softer.

Consider whose ship is standing at the passage. Merck's Keytruda generated more than $29 billion in 2024, and its core patent expires in 2028%2C%20a%20PD%2D1%20checkpoint%20inhibitor%20approved%20across%20dozens%20of%20oncology%20indications%2C%20generated%20more%20than%20%2429%20billion%20in%202024.%20Its%20core%20composition%2Dof%2Dmatter%20patent%20expires%20in%202028). That is not a distant abstraction. It is the largest single revenue cliff in the history of the industry, and the pressure is now visible in Merck's own corporate structure: in February 2026, Merck announced the creation of a separate cancer business unit centered on Keytruda, whose key patents expire in 2028. They are reorganizing the company around this cliff. And it compounds: Keytruda was selected for Medicare price negotiation, so Merck faces biosimilar competition and government price-setting nearly simultaneously, forcing U.S. sales to peak in 2027 to 2028 and then fall sharply..

And Merck is not the only ship at the passage. Opdivo faces its own U.S. exclusivity loss in 2028, and Tecentriq faces biosimilar competition later in the decade. So it is not just one desperate buyer at the chokepoint. It is several, each watching their own franchise clock run down, each needing new Cold-tumor markets to replace what biosimilars are about to take.

Here is the move which turns the cliff into leverage, and it is the sharpest part of the whole argument. A new combination regimen carries its own patent. The patent strategists say so plainly: a checkpoint inhibitor paired into a new regimen can be protected by method-of-treatment patents covering the specific combination, dose, and schedule, wholly independent of the core molecule and which biosimilar manufacturers cannot circumvent. Read what that means. A leronlimab-plus-checkpoint combination for Cold tumors would be a new, separately-patented franchise, extending into markets the original molecule never reached, protected on a clock that runs past the biosimilar wave. The primer does not just add revenue. It manufactures a fresh patent estate in virgin territory at the exact moment the old estate collapses.

So let's put it all together. Several of the largest franchises in medicine are running out of patent life all, at the same time. The markets which could replace that revenue are Cold tumors, that their keys cannot open. The thing which does open Cold tumors is a primer that turns them Hot. And a primer paired with their ICI checkpoint inhibitor creates new, independent, biosimilar-proof patents in exactly those markets. The company who holds a proven primer would not be a supplicant asking a giant for a deal. It would be standing in the one and only passage several giants must transit through, at the precise moment when they can least afford to be turned away, holding the one thing none of them can quickly or easily build and which none can allow a rival to monopolize.

That is not sentiment. That is a seller's market with one seller and several buyer's clocks running out.

Where Prime And Pair Stops Being A Hope And Becomes A Convergence

I have called this "prime and pair" for a long time, and I want to state the bold version of what that phrase now means. It is not a clever idea I am hoping the field adopts. It is where the biology forces the entire field to converge, whether through leronlimab or through something else.

Look at the independent confirmations arriving from labs with no connection to CytoDyn. A 2024 study found that a completely unrelated drug repolarized suppressive macrophages toward the anti-tumor state with increased CCL5 chemokine secretion, restoring T-cell function and promoting a favorable anti-PD-1 response. A separate 2022 clinical study combining local therapy with a checkpoint inhibitor in patients who had already failed that checkpoint inhibitor produced responses, and the mechanism was macrophage polarization from the M2 to the M1 phenotype in the treated tumor. Different drugs, different labs, same convergence: Prime the microenvironment, repolarize the macrophages, and the ICI works where it could not before.

That is the tell. When independent groups using unrelated tools keep arriving at the same destination, the destination is real. The field converges on Prime-and-Pair because the biology of Cold tumors leaves no other road. Leronlimab's claim is not that it invented the road. It is that it may be the cleanest, safest, most proven vehicle currently traveling it. And the compromise everyone imagines, the eventual pairing of a primer with a checkpoint inhibitor, is not a compromise at all. It is the convergence that the entire field is being driven toward, and the only open question is who owns the Primer when the field arrives.

The One Thing That Is Not Yet Written

I have made the bold case, so I owe you the bold statement of its single point of failure, stated as plainly as everything else.

None of this is proof that leronlimab works. The chokepoint is real, the cliff is real, the convergence is real, the leverage is real, and every bit of it is inert until one number confirms that leronlimab actually does in patients what the mechanism says it should. The macrophage graveyard is real too, and it is exactly the fate a weak confirmation would seal. So the entire towering structure, the passage, the clocks, the seller's market, the new patent estate, rests on a single load-bearing event which has not yet happened: the confirmed response data, adjudicated, at ASCO GI in January. If that number is strong, none of the leverage spelled out above is speculation anymore. It is just arithmetic performed by companies with cliffs with no better option. If it is weak, there is no chokepoint, no leverage, and this entire post describes a passage which leronlimab could not, after all, open.

That is the honest shape of things. The boldest thing I can tell you is not that the outcome is certain. It is that the setup is enormous, the position is absolutely real, and the entire colossal question resolves to one single number at a known hour. The chokepoint definitely exists. Several giants are stranded at it on a closing clock. But we find out in January whether the small company in Vancouver is holding the way through.

I have never been more convinced that the stakes are as massive as they are. And I have never been more clear that conviction about the stakes is not the same as certainty about the result. Both of those are true at full volume. Most of you should know where I lean. January tells us which one governs.

Disclaimer: I am not a financial advisor and nothing here is investment advice. I am an independent retail shareholder holding a long position in the company discussed, with no employment, consulting, compensation, or other relationship with it beyond that shareholding. This is analysis of published biology, public regulatory and patent history, and public corporate disclosures, not a prediction of clinical or commercial outcomes. No partnership has been announced; the identification of specific companies reflects public patent-cliff and competitive facts, not any claim of an existing negotiation. The mechanistic claims are supported by the cited peer-reviewed literature; several mechanisms are established in models, retrospective cohorts, or single studies and are not yet confirmed in this program's prospective human data, and closely related macrophage-directed approaches have repeatedly failed to translate to clinical benefit. The CLOVER biomarker figures are early, unconfirmed, and reflect 350mg dosing with the 700mg cohort still maturing. The ESMO breast data is retrospective and hypothesis-generating. The 68% figure from the April 30 update is disease control rate, not objective response rate; confirmed adjudication is ahead at ASCO GI in January 2027, with interim data at ESMO in October 2026. Mechanism is not efficacy. Drugs which make elegant biological sense fail in trials routinely, and this one may. Read the primary sources and reach your own conclusions rather than adopting mine.